Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders

ABSTRACT

The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/994,213, filed on Jan. 13, 2016, which is a continuation of U.S.application Ser. No. 13/143,505, filed on Nov. 1, 2011 (now U.S. Pat.No. 9,266,890, issued on Feb. 23, 2016), which is a 35 U.S.C. §371 U.S.national stage entry of International Application PCT/US2010/000050 (WO2010/080712) having an International filing date of Jan. 6, 2010, whichclaims the benefit of U.S. Provisional Application No. 61/193,901, filedon Jan. 6, 2009. The entire contents of each of the above applicationsare incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to novel pyrimido-diazepinone compoundswhich are able to modulate protein kinases, including MPS1 (TTK), ERK5(BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1,ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2,PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1,GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit,CHK2, Flt3, MST2, p70S6K, PDGFK, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA,TrkB and TrkC, and the use of such compounds in the treatment of variousdiseases, disorders or conditions.

BACKGROUND OF THE INVENTION

Protein kinases represent a large family of proteins, which play acentral role in the regulation of a wide variety of cellular processesand maintaining control over cellular function. Protein kinasesconstitute a large family of structurally related enzymes that areresponsible for the control of a variety of signal transductionprocesses within the cell (see Hardie, G and Hanks, S. The ProteinKinase Facts Book, I and II, Academic Press, San Diego, Calif.: 1995).Protein kinases are thought to have evolved from a common ancestral genedue to the conservation of their structure and catalytic function.Almost all kinases contain a similar 250-300 amino acid catalyticdomain. The kinases may be categorized into families by the substratesthey phosphorylate (e.g., protein-tyrosine, protein-serine/threonine,lipids etc).

In general, protein kinases mediate intracellular signaling bycatalyzing a phosphoryl transfer from a nucleoside triphosphate to aprotein acceptor that is involved in a signaling pathway. Thesephosphorylation events act as molecular on/off switches that canmodulate or regulate the target protein biological function. Thesephosphorylation events are ultimately triggered in response to a varietyof extracellular and other stimuli. Examples of such stimuli includeenvironmental and chemical stress signals (e.g., shock, heat shock,ultraviolet radiation, bacterial endotoxin, and H2O2), cytokines (e.g.,interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α), and growthfactors (e.g., granulocyte macrophage-colony stimulating factor(GM-CSF), and fibroblast growth factor (FGF)). An extracellular stimulusmay affect one or more cellular responses related to cell growth,migration, differentiation, secretion of hormones, activation oftranscription factors, muscle contraction, glucose metabolism, controlof protein synthesis, survival and regulation of the cell cycle.

A partial, non-limiting, list of these kinases include: receptortyrosine kinases such as platelet-derived growth factor receptor kinase(PDGF-R), the nerve growth factor receptor, Trk-A, —B and —C, and thefibroblast growth factor receptor, FGFR3; non-receptor tyrosine kinasessuch Ab1 and the fusion kinase BCR-Ab1, Lck, Csk, Fes, BTK, Bmx andc-src; and serine/threonine kinases such as Aurora, c-RAF, SGK, MAPkinases (e.g., MKK4, MKK6, etc.) and SAPK2α and SAPK2β. Aberrant kinaseactivity has been observed in many disease states including benign andmalignant proliferative disorders as well as diseases resulting frominappropriate activation of the immune and nervous systems.

The novel compounds of this invention inhibit the activity of one ormore protein kinases and are, therefore, expected to be useful in thetreatment of kinase-associated diseases.

SUMMARY OF THE INVENTION

In one aspect, the invention provides a compound of formula A:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

X is CHR₄, CR₄, NH, NR₄ or N;

Y is NR₅, N, S, SO, SO₂, O, CHR₅, or CR₅; wherein at least one of X andY is NH, NR₄, NR₅, N, S, SO, SO₂, or O;

A is a single bond or double bond;

B is a single bond or double bond, wherein both A and B are not doublebonds;

R′ is H or alkyl;

L is absent, S, SO, SO₂, or CO;

R₁ is H, alkyl, alkenyl, alkynyl, each containing 0, 1, 2, or 3heteroatoms selected from O, S, or N; or R₁ is aryl, arylalkyl,heteroaryl, heterocyclic, or carbocyclic; wherein R₁ may be optionallysubstituted;

R₂ is hydrogen or optionally substituted alkyl;

R₃ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

R₄ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

R₅ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

or R₃ and X, together with the atoms to which they are attached, form a3-8 membered carbocyclic, aryl, heterocyclic, or heteroaryl; each ofwhich is optionally substituted;

or X and Y, together with the atoms to which they are attached, form a3-8 membered carbocyclic, aryl, heterocyclic, or heteroaryl; each ofwhich is optionally substituted; and

R₆ is hydrogen or optionally substituted alkyl.

In another aspect, the invention provides a method of treating a diseasein a subject comprising administering to the subject a compound,pharmaceutically acceptable salt, ester or prodrug of formula A.

In another aspect, the invention provides a method of treating a kinasemediated disorder in a subject comprising: administering to the subjectidentified as in need thereof a compound, pharmaceutically acceptablesalt, ester or prodrug of formula A.

In another aspect, the invention provides a method for reducingkinase-dependent cell growth comprising contacting a cell with a kinaseinhibitor compound of formula A.

In other aspects, the invention provides a method of inhibiting kinasein a subject identified as in need of such treatment, comprisingadministering a compound of formula A.

In another aspect, the invention provides a kit comprising a compoundcapable of inhibiting kinase activity selected from one or morecompounds of claim 1, and instructions for use in treating cancer.

In another aspect, the invention provides a pharmaceutical compositioncomprising a compound of formula A, or a pharmaceutically acceptableester, salt, or prodrug thereof, together with a pharmaceuticallyacceptable carrier.

In one aspect, the invention provides a method of synthesizing acompound of formula A.

DESCRIPTION OF THE DRAWINGS

FIG. 1. Mps1 inhibitor I-10 induces escape from mitosis. Hela cells werearrested in mitosis using the following protocol. Cells were treatedwith thymidine (2.5 mM) for 24 hours. Cells were released into mediumcontaining nocodazole (0.33 μM). After 16 hrs. cells were treated withI-10 a range of concentrations (0.25, 0.5, 1, 2, 5 and 10 uM) shownabove for 2 hrs. Cells were harvested and the levels of cyclin B (amarker for mitosis) were determined by immunoblot. High cyclin B levelsindicated mitotic cells, while low cyclin B levels indicate cells haveexited nocodazole-induced mitotic arrest.

FIG. 2. Plk1 inhibitors I-3 and I-12 induce mitotic arrest. Usingimmunofluorescence microscopy the cells were located by their DNA stain(Hoechst) and were then scored for phospho H3 positivity. Cells that arearrested in mitosis are phospho H3 positive. Chemical inhibition of Plk1has been shown to cause a mitotic arrest and thus an increase in phosphoH3 signal. Compounds were ranked for their Plk1 activity based on thepercentage of cells exhibiting a mitotic arrest phenotype as exemplifiedby high phospho H3 positivity.

FIG. 3. Compounds I-3, I-4, I-5 induce a strong mitotic arrest whilecompounds I-6, I-7, I-8, and I-12 do not. Results quantitated from Plk1Mitotic Arrest assay as described in FIG. 2.

FIG. 4. Dose-response curves for inhibitors in a Mps1 biochemical kinaseassay. Results were obtained using Invitrogen's Mps1 (TTK) LanthaScreenActivity Assay.

FIG. 5. IC₅₀ values for inhibition of Mps1 kinase activity. The IC₅₀values for the compounds shown above were calculated from the raw datain the previous figure. Staurosporine was used as a reference compound(IC₅₀ on Mps1 kinase activity=1388 nM).

FIG. 6. In vitro Plk1 binding assay: Ambit K_(d) values in nanomolar.K_(d) values generated by Ambit binding assay over a concentration rangeof the compound.

FIG. 7. In vitro Erk5 binding assay: Ambit K_(d) values in nanomolar.K_(d) values generated by Ambit binding assay over a concentration rangeof the compound.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Listed below are definitions of various terms used to describe thisinvention. These definitions apply to the terms as they are usedthroughout this specification and claims, unless otherwise limited inspecific instances, either individually or as part of a larger group.

The term “alkyl,” as used herein, refers to saturated, straight- orbranched-chain hydrocarbon radicals containing, in certain embodiments,between one and six, or one and eight carbon atoms, respectively.Examples of C₁-C₆ alkyl radicals include, but are not limited to,methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl,n-hexyl radicals; and examples of C₁-C₈ alkyl radicals include, but arenot limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl,neopentyl, n-hexyl, heptyl, octyl radicals.

The term “alkenyl,” as used herein, denotes a monovalent group derivedfrom a hydrocarbon moiety containing, in certain embodiments, from twoto six, or two to eight carbon atoms having at least one carbon-carbondouble bond. The double bond may or may not be the point of attachmentto another group. Alkenyl groups include, but are not limited to, forexample, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl,octenyl and the like.

The term “alkynyl,” as used herein, denotes a monovalent group derivedfrom a hydrocarbon moiety containing, in certain embodiments, from twoto six, or two to eight carbon atoms having at least one carbon-carbontriple bond. The alkynyl group may or may not be the point of attachmentto another group. Representative alkynyl groups include, but are notlimited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl,octynyl and the like.

The term “alkoxy” refers to an —O-alkyl radical.

The term “aryl,” as used herein, refers to a mono- or poly-cycliccarbocyclic ring system having one or more aromatic rings, fused ornon-fused, including, but not limited to, phenyl, naphthyl,tetrahydronaphthyl, indanyl, idenyl and the like.

The term “aralkyl,” as used herein, refers to an alkyl residue attachedto an aryl ring. Examples include, but are not limited to, benzyl,phenethyl and the like.

The term “cycloalkyl,” as used herein, denotes a monovalent groupderived from a monocyclic or polycyclic saturated or partially unsaturedcarbocyclic ring compound. Examples of C₃-C₈-cycloalkyl include, but notlimited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cyclopentyl and cyclooctyl; and examples of C₃-C₁₂-cycloalkyl include,but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl. Also contemplated area monovalent group derived from a monocyclic or polycyclic carbocyclicring compound having at least one carbon-carbon double bond by theremoval of a single hydrogen atom. Examples of such groups include, butare not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl,cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like.

The term “heteroaryl,” as used herein, refers to a mono- or poly-cyclic(e.g., bi-, or tri-cyclic or more) fused or non-fused, radical or ringsystem having at least one aromatic ring, having from five to ten ringatoms of which one ring atoms is selected from S, O and N; zero, one ortwo ring atoms are additional heteroatoms independently selected from S,O and N; and the remaining ring atoms are carbon. Heteroaryl includes,but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl,pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl,oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl,benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like.

The term “heteroaralkyl,” as used herein, refers to an alkyl residueattached to a heteroaryl ring. Examples include, but are not limited to,pyridinylmethyl, pyrimidinylethyl and the like.

The term “heterocycloalkyl,” as used herein, refers to a non-aromatic3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused ofnon-fused system, where (i) each ring contains between one and threeheteroatoms independently selected from oxygen, sulfur and nitrogen,(ii) each 5-membered ring has 0 to 1 double bonds and each 6-memberedring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatomsmay optionally be oxidized, (iv) the nitrogen heteroatom may optionallybe quaternized, and (iv) any of the above rings may be fused to abenzene ring. Representative heterocycloalkyl groups include, but arenot limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl,pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl,oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl,isothiazolidinyl, and tetrahydrofuryl.

The term “alkylamino” refers to a group having the structure —NH(C₁-C₁₂alkyl) where C₁-C₁₂ alkyl is as previously defined.

The term “acyl” includes residues derived from acids, including but notlimited to carboxylic acids, carbamic acids, carbonic acids, sulfonicacids, and phosphorous acids. Examples include aliphatic carbonyls,aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphaticsulfinyls, aromatic phosphates and aliphatic phosphates. Examples ofaliphatic carbonyls include, but are not limited to, acetyl, propionyl,2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.

In accordance with the invention, any of the aryls, substituted aryls,heteroaryls and substituted heteroaryls described herein, can be anyaromatic group. Aromatic groups can be substituted or unsubstituted.

The terms “halo” and “halogen,” as used herein, refer to an atomselected from fluorine, chlorine, bromine and iodine.

As described herein, compounds of the invention may optionally besubstituted with one or more substituents, such as are illustratedgenerally above, or as exemplified by particular classes, subclasses,and species of the invention. It will be appreciated that the phrase“optionally substituted” is used interchangeably with the phrase“substituted or unsubstituted.” In general, the term “substituted”,whether preceded by the term “optionally” or not, refers to thereplacement of hydrogen radicals in a given structure with the radicalof a specified substituent. Unless otherwise indicated, an optionallysubstituted group may have a substituent at each substitutable positionof the group, and when more than one position in any given structure maybe substituted with more than one substituent selected from a specifiedgroup, the substituent may be either the same or different at everyposition. The terms “optionally substituted”, “optionally substitutedalkyl,” “optionally substituted “optionally substituted alkenyl,”“optionally substituted alkynyl”, “optionally substituted cycloalkyl,”“optionally substituted cycloalkenyl,” “optionally substituted aryl”,“optionally substituted heteroaryl,” “optionally substituted aralkyl”,“optionally substituted heteroaralkyl,” “optionally substitutedheterocycloalkyl,” and any other optionally substituted group as usedherein, refer to groups that are substituted or unsubstituted byindependent replacement of one, two, or three or more of the hydrogenatoms thereon with substituents including, but not limited to:

—F, —Cl, —Br, —I,

—OH, protected hydroxy,

—NO₂, —CN,

—NH₂, protected amino, —NH—C₁-C₁₂-alkyl, —NH—C₂-C₁₂-alkenyl,—NH—C₂-C₁₂-alkenyl, —NH—C₃-C₁₂-cycloalkyl, —NH-aryl, —NH-heteroaryl,—NH-heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino,

—O—C₁-C₁₂-alkyl, —O—C₂-C₁₂-alkenyl, —O—C₂-C₁₂-alkenyl,—O—C₃-C₁₂-cycloalkyl, —O-aryl, —O-heteroaryl, —O-heterocycloalkyl,

—C(O)—C₁-C₁₂-alkyl, —C(O)—C₂-C₁₂-alkenyl, —C(O)—C₂-C₁₂-alkenyl,—C(O)—C₃-C₁₂-cycloalkyl, —C(O)-aryl, —C(O)-heteroaryl,—C(O)-heterocycloalkyl,

—CONH₂, —CONH—C₁-C₁₂-alkyl, —CONH—C₂-C₁₂-alkenyl, —CONH—C₂-C₁₂-alkenyl,—CONH—C₃-C₁₂-cycloalkyl, —CONH-aryl, —CONH-heteroaryl, —CONH—heterocycloalkyl,

—OCO₂—C₁-C₁₂-alkyl, —OCO₂—C₂-C₁₂-alkenyl, —OCO₂—C₂-C₁₂-alkenyl,—OCO₂—C₃-C₁₂-cycloalkyl, —OCO₂-aryl, —OCO₂-heteroaryl,—OCO₂-heterocycloalkyl, —OCONH₂, —OCONH—C₁-C₁₂-alkyl,—OCONH—C₂-C₁₂-alkenyl, —OCONH—C₂-C₁₂-alkenyl, —OCONH—C₃-C₁₂-cycloalkyl,—OCONH-aryl, —OCONH-heteroaryl, —OCONH-heterocycloalkyl,

—NHC(O)—C₁-C₁₂-alkyl, —NHC(O)—C₂-C₁₂-alkenyl, —NHC(O)—C₂-C₁₂-alkenyl,—NHC(O)—C₃-C₁₂-cycloalkyl, —NHC(O)-aryl, —NHC(O)-heteroaryl, —NHC(O)—heterocycloalkyl, —NHCO₂—C₁-C₁₂-alkyl, —NHCO₂—C₂-C₁₂-alkenyl,—NHCO₂—C₂-C₁₂-alkenyl, —NHCO₂—C₃-C₁₂-cycloalkyl, —NHCO₂-aryl,—NHCO₂-heteroaryl, —NHCO₂— heterocycloalkyl, —NHC(O)NH₂,—NHC(O)NH—C₁-C₁₂-alkyl, —NHC(O)NH—C₂-C₁₂-alkenyl,—NHC(O)NH—C₂-C₁₂-alkenyl, —NHC(O)NH—C₃-C₁₂-cycloalkyl, —NHC(O)NH-aryl,—NHC(O)NH-heteroaryl, —NHC(O)NH-heterocycloalkyl, NHC(S)NH₂,—NHC(S)NH—C₁-C₁₂-alkyl, —NHC(S)NH—C₂-C₁₂-alkenyl,—NHC(S)NH—C₂-C₁₂-alkenyl, —NHC(S)NH—C₃-C₁₂-cycloalkyl, —NHC(S)NH-aryl,—NHC(S)NH-heteroaryl, —NHC(S)NH-heterocycloalkyl, —NHC(NH)NH₂,—NHC(NH)NH—C₁-C₁₂-alkyl, —NHC(NH)NH—C₂-C₁₂-alkenyl,—NHC(NH)NH—C₂-C₁₂-alkenyl, —NHC(NH)NH—C₃-C₁₂-cycloalkyl,—NHC(NH)NH-aryl, —NHC(NH)NH-heteroaryl, —NHC(NH)NH— heterocycloalkyl,—NHC(NH)—C₁-C₁₂-alkyl, —NHC(NH)—C₂-C₁₂-alkenyl, —NHC(NH)—C₂-C₁₂-alkenyl,—NHC(NH)—C₃-C₁₂-cycloalkyl, —NHC(NH)-aryl, —NHC(NH)— heteroaryl,—NHC(NH)-heterocycloalkyl,

—C(NH)NH—C₁-C₁₂-alkyl, —C(NH)NH—C₂-C₁₂-alkenyl, —C(NH)NH—C₂-C₁₂-alkenyl,—C(NH)NH—C₃-C₁₂-cycloalkyl, —C(NH)NH-aryl, —C(NH)NH-heteroaryl,—C(NH)NH-heterocycloalkyl,

—S(O)—C₁-C₁₂-alkyl, —S(O)—C₂-C₁₂-alkenyl, —S(O)—C₂-C₁₂-alkenyl,—S(O)—C₃-C₁₂-cycloalkyl, —S(O)-aryl, —S(O)-heteroaryl,—S(O)-heterocycloalkyl —SO₂NH₂, —SO₂NH—C₁-C₁₂-alkyl,—SO₂NH—C₂-C₁₂-alkenyl, —SO₂NH—C₂-C₁₂-alkenyl, —SO₂NH—C₃-C₁₂-cycloalkyl,—SO₂NH-aryl, —SO₂NH-heteroaryl, —SO₂NH-heterocycloalkyl,

—NHSO₂—C₁-C₁₂-alkyl, —NHSO₂—C₂-C₁₂-alkenyl, —NHSO₂—C₂-C₁₂-alkenyl,—NHSO₂—C₃-C₁₂-cycloalkyl, —NHSO₂-aryl, —NHSO₂-heteroaryl, —NHSO₂—heterocycloalkyl,

—CH₂NH₂, —CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl,-heterocycloalkyl, —C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy,-methoxymethoxy, -methoxyethoxy, —SH, —S—C₁-C₁₂-alkyl,—S—C₂-C₁₂-alkenyl, —S—C₂-C₁₂-alkenyl, —S—C₃-C₁₂-cycloalkyl, —S-aryl,—S-heteroaryl, —S-heterocycloalkyl, or methylthiomethyl.

It is understood that the aryls, heteroaryls, alkyls, and the like canbe further substituted.

The term “cancer” includes, but is not limited to, the followingcancers: epidermoid Oral: buccal cavity, lip, tongue, mouth, pharynx;Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma,liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung:bronchogenic carcinoma (squamous cell or epidermoid, undifferentiatedsmall cell, undifferentiated large cell, adenocarcinoma), alveolar(bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma,chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus(squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma,lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoidtumors, vipoma), small bowel or small intestines (adenocarcinoma,lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma,lipoma, neurofibroma, fibroma), large bowel or large intestines(adenocarcinoma, tubular adenoma, villous adenoma, hamartoma,leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinarytract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma,leukemia), bladder and urethra (squamous cell carcinoma, transitionalcell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma),testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma,choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma(hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma,angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages;Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibroushistiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma(reticulum cell sarcoma), multiple myeloma, malignant giant cell tumorchordoma, osteochronfroma (osteocartilaginous exostoses), benignchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma andgiant cell tumors; Nervous system: skull (osteoma, hemangioma,granuloma, xanthoma, osteitis deformans), meninges (meningioma,meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform,oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological:uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumorcervical dysplasia), ovaries (ovarian carcinoma [serouscystadenocarcinoma, mucinous cystadenocarcinoma, unclassifiedcarcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors,dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma,intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma),vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma(embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast;Hematologic: blood (myeloid leukemia [acute and chronic], acutelymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferativediseases, multiple myeloma, myelodysplastic syndrome), Hodgkin'sdisease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell;lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma,squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, molesdysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis,Thyroid gland: papillary thyroid carcinoma, follicular thyroidcarcinoma; medullary thyroid carcinoma, undifferentiated thyroid cancer,multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma;and Adrenal glands: neuroblastoma. Thus, the term “cancerous cell” asprovided herein, includes a cell afflicted by any one of theabove-identified conditions.

The term “Kinase Panel” is a list of kinases comprising MPS1 (TTK), ERK5(BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1,ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2,PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1,GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit,CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA,TrkB, TrkC, AAK1, ABL1, ABL1(E255K), ABL1(F317I), ABL1(F317L),ABL1(H396P), ABL1(M351T), ABL1(Q252H), ABL1(T315I), ABL1(Y253F), ABL2,ACVR1, ACVR1B, ACVR2A, ACVR2B, ACVRL1, ADCK3, ADCK4, AKT1, AKT2, AKT3,ALK, AMPK-alpha1, AMPK-alpha2, ANKK1, ARK5, ASK1, ASK2, AURKA, AURKB,AURKC, AXL, BIKE, BLK, BMPR1A, BMPR1B, BMPR2, BMX, BRAF, BRAF(V600E),BRK, BRSK1, BRSK2, BTK, CAMK1, CAMK1D, CAMK1G, CAMK2A, CAMK2D, CAMK2G,CAMK4, CAMKK1, CAMKK2, CDC2L1, CDC2L2, CDK11, CDK2, CDK3, CDK5, CDK7,CDK8, CDK9, CDKL2, CDKL3, CDKL5, CHECK1, CHEK2, CIT, CLK1, CLK2, CLK3,CLK4, CSF1R, CSK, CSNK1A1L, CSNK1D, CSNK1E, CSNK1G1, CSNK1G3, CSNK2A1,CSNK2A2, CTK, DAPK1, DAPK2, DAPK3, DCAMKL1, DCAMKL2, DCAMKL3, DDR1,DDR2, DLK, DMPK, DMPK2, DRAK1, DRAK2, DYRKIA, DYRKIB, DYRK2, EGFR, EGFR(E746-A750DEL), EGFR (G719C), EGFR (G719S), EGFR(L747-E749del, A750P),EGFR(L747-S752del, P753S), EGFR(L747-T751del,Sins), EGFR(L858R),EGFR(L858R,T790M), EGFR(L861Q), EGFR(S752-I759del), EPHA1, EPHA2, EPHA3,EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6,ERBB2, ERBB3, ERBB4, ERK1, ERK2, ERK3, ERK4, ERK5, ERK8, ERN1, FAK, FER,FES, FGFR1, FGFR2, FGFR3, FGFR3(G697C), FGFR4, FGR, FLT1, FLT3,FLT3(D835H), FLT3(D835Y), FLT3(ITD), FLT3(K663Q), FLT3(N841I), FLT4,FRK, FYN, GAK, GCN2(Kin.Dom.2,S808G), GRK1, GRK4, GRK7, GSK3A, GSK3B,HCK, HIPK1, HIPK2, HIPK3, HIPK4, HPK1, HUNK, ICK, IGF1R, IKK-ALPHA,IKK-BETA, IKK-EPSILON, INSR, INSRR, IRAK1, IRAK3, ITK,JAK1(JH1domain-catalytic), JAK1(JH2domain-pseudokinase),JAK2(JH1domain-catalytic), JAK3(JH domain-catalytic), JNK1, JNK2, JNK3,KIT, KIT(D816V), KIT(L576P), KIT(V559D), KIT(V559D,T670I),KIT(V559D,V654A), LATS1, LATS2, LCK, LIMK1, LIMK2, LKB1, LOK, LTK, LYN,LZK, MAK, MAP3K1, MAP2K15, MAP3K2, MAP3K3, MAP3K4, MAP4K2, MAP4K3,MAP4K5, MAPKAPK2, MAPKAPK5, MARK1, MARK2, MARK3, MARK4, MAST1, MEK1,MEK2, MEK3, MEK4, MEK6, MELK, MERTK, MET, MET(M1250T), MET(Y1235D),MINK, MKNK1, MKNK2, MLCK, MLK1, MLK2, MLK3, MRCKA, MRCKB, MST1, MST1R,MST2, MST3, MST4, MUSK, MYLK, MYLK2, MYO3A, MYO3B, NDR1, NDR2, NEK1,NEK2, NEK5, NEK6, NEK7, NEK9, NIM1, NLK, OSR1, p38-alpha, p38-beta,p38-delta, p38-gamma, PAK1, PAK2, PAK3, PAK4, PAK6, PAK7, PCTK1, PCTK2,PCTK3, PDGFRA, PDGFRB, PDPK1, PFTAIRE2, PFTK1, PHKG1, PHKG2, PIK3C2B,PIK3C2G, PIK3CA, PIK3CA(C420R), PIK3CA(E542K), PIK3CA(E545A),PIK3CA(E545K), PIK3CA(H1047L), PIK3CA(H1047Y), PIK3CA(M1043I),PIK3CA(Q546K), PIK3CB, PIK3CD, PIK3CG, PIK4CB, PIM1, PIM2, PIM3,PIP5K1A, PIP5K2B, PKAC-ALPHA, PKAC-BETA, PKMYT1, PKN1, PKN2, PLK1, PLK2,PLK3, PLK4, PRKCD, PRKCE, PRKCH, PRKCQ, PRKD1, PRKD3, PRKG1, PRKG2,PRKR, PRKX, PRP4, PYK2, QSK, RAF1, RET, RET(M918T), RET(V804L),RET(V804M), RIOK1, RIOK2, RIOK3, RIPK1, RIPK2, RIPK4, ROCK1, ROCK2,ROS1, RPS6KA1(Kin.Dom.1-N-terminal), RPS6KA1(Kin.Dom.2-C-terminal),RPS6KA2(Kin.Dom.1-N-terminal), RPS6KA2(Kin.Dom.2-C-terminal),RPS6KA3(Kin.Dom.1-N-terminal), RPS6KA4(Kin.Dom.1-N-terminal),RPS6KA4(Kin.Dom.2-C-terminal), RPS6KA5(Kin.Dom.1-N-terminal),RPS6KA5(Kin.Dom.2-C-terminal), RPS6KA6(Kin.Dom.1-N-terminal),RPS6KA6(Kin.Dom.2-C-terminal), SBK1, SgK085, SgK110, SIK, SIK2, SLK,SNARK, SRC, SRMS, SRPK1, SRPK2, SRPK3, STK16, STK33, STK39, SYK, TAK1,TAO1, TAOK2, TAOK3, TBK1, TEC, TESK1, TGFBR1, TGFBR2, TIE1, TIE2, TLK1,TLK2, TNIK, TNK1, TNK2, TNNI3K, TRKA, TRKB, TRKC, TSSK1B, TTK, TXK,TYK2(JH1domain-catalytic), TYK2(JH2domain-pseudokinase), TYRO3, ULK1,ULK2, ULK3, VEGFR2, WEE1, WEE2, YANK2, YANK3, YES, YSK1, YSK4, ZAK andZAP70. Compounds of the invention are screened against the kinase panel(wild type and/or mutation thereof) and inhibit the activity of at leastone of said panel members.

Mutant forms of a kinase means single or multiple amino acid changesfrom the wild-type sequence.

The term “subject” as used herein refers to a mammal. A subjecttherefore refers to, for example, dogs, cats, horses, cows, pigs, guineapigs, and the like.

Preferably the subject is a human. When the subject is a human, thesubject may be referred to herein as a patient.

Treat”, “treating” and “treatment” refer to a method of alleviating orabating a disease and/or its attendant symptoms.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts of the compounds formed by the process of the presentinvention which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like, andare commensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M. Berge, etal. describes pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared insitu during the final isolation and purification of the compounds of theinvention, or separately by reacting the free base function with asuitable organic acid. Examples of pharmaceutically acceptable include,but are not limited to, nontoxic acid addition salts are salts of anamino group formed with inorganic acids such as hydrochloric acid,hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid orwith organic acids such as acetic acid, maleic acid, tartaric acid,citric acid, succinic acid or malonic acid or by using other methodsused in the art such as ion exchange. Other pharmaceutically acceptablesalts include, but are not limited to, adipate, alginate, ascorbate,aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate,camphorate, camphorsulfonate, citrate, cyclopentanepropionate,digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate,hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts,and the like. Representative alkali or alkaline earth metal saltsinclude sodium, lithium, potassium, calcium, magnesium, and the like.Further pharmaceutically acceptable salts include, when appropriate,nontoxic ammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate,nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and arylsulfonate.

As used herein, the term “pharmaceutically acceptable ester” refers toesters of the compounds formed by the process of the present inventionwhich hydrolyze in vivo and include those that break down readily in thehuman body to leave the parent compound or a salt thereof. Suitableester groups include, for example, those derived from pharmaceuticallyacceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic,cycloalkanoic and alkanedioic acids, in which each alkyl or alkenylmoiety advantageously has not more than 6 carbon atoms. Examples ofparticular esters include, but are not limited to, formates, acetates,propionates, butyrates, acrylates and ethylsuccinates.

The term “pharmaceutically acceptable prodrugs” as used herein refers tothose prodrugs of the compounds formed by the process of the presentinvention which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswith undue toxicity, irritation, allergic response, and the like,commensurate with a reasonable benefit/risk ratio, and effective fortheir intended use, as well as the zwitterionic forms, where possible,of the compounds of the present invention. “Prodrug”, as used hereinmeans a compound which is convertible in vivo by metabolic means (e.g.by hydrolysis) to afford any compound delineated by the formulae of theinstant invention. Various forms of prodrugs are known in the art, forexample, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier(1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, AcademicPress (1985); Krogsgaard-Larsen, et al., (ed). “Design and Applicationof Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191(1991); Bundgaard, et al., Journal of Drug Deliver Reviews,8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.(1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug DeliverySystems, American Chemical Society (1975); and Bernard Testa & JoachimMayer, “Hydrolysis In Drug And Prodrug Metabolism: Chemistry,Biochemistry And Enzymology,” John Wiley and Sons, Ltd. (2002).

This invention also encompasses pharmaceutical compositions containing,and methods of treating disorders through administering,pharmaceutically acceptable prodrugs of compounds of the invention. Forexample, compounds of the invention having free amino, amido, hydroxy orcarboxylic groups can be converted into prodrugs. Prodrugs includecompounds wherein an amino acid residue, or a polypeptide chain of twoor more (e.g., two, three or four) amino acid residues is covalentlyjoined through an amide or ester bond to a free amino, hydroxy orcarboxylic acid group of compounds of the invention. The amino acidresidues include but are not limited to the 20 naturally occurring aminoacids commonly designated by three letter symbols and also includes4-hydroxyproline, hydroxyysine, demosine, isodemosine,3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid,citrulline, homocysteine, homoserine, ornithine and methionine sulfone.Additional types of prodrugs are also encompassed. For instance, freecarboxyl groups can be derivatized as amides or alkyl esters. Freehydroxy groups may be derivatized using groups including but not limitedto hemisuccinates, phosphate esters, dimethylaminoacetates, andphosphoryloxymethyloxy carbonyls, as outlined in Advanced Drug DeliveryReviews, 1996, 19, 1 15. Carbamate prodrugs of hydroxy and amino groupsare also included, as are carbonate prodrugs, sulfonate esters andsulfate esters of hydroxy groups. Derivatization of hydroxy groups as(acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may bean alkyl ester, optionally substituted with groups including but notlimited to ether, amine and carboxylic acid functionalities, or wherethe acyl group is an amino acid ester as described above, are alsoencompassed. Prodrugs of this type are described in J. Med. Chem. 1996,39, 10. Free amines can also be derivatized as amides, sulfonamides orphosphonamides. All of these prodrug moieties may incorporate groupsincluding but not limited to ether, amine and carboxylic acidfunctionalities

Combinations of substituents and variables envisioned by this inventionare only those that result in the formation of stable compounds. Theterm “stable”, as used herein, refers to compounds which possessstability sufficient to allow manufacture and which maintains theintegrity of the compound for a sufficient period of time to be usefulfor the purposes detailed herein (e.g., therapeutic or prophylacticadministration to a subject).

Compounds of the Invention

In one aspect, the invention provides a compound of formula A:

or a pharmaceutically acceptable salt, ester or prodrug thereof,wherein,

X is CHR₄, CR₄, NH, NR₄ or N;

Y is NR₅, N, S, SO, SO₂, O, CHR₅, or CR₅; wherein at least one of X andY is NH, NR₄, NR₅, N, S, SO, SO₂, or O;

A is a single bond or double bond;

B is a single bond or double bond, wherein both A and B are not doublebonds;

R′ is H or alkyl;

L is absent, S, SO, SO₂, or CO;

R₁ is H, alkyl, alkenyl, alkynyl, each containing 0, 1, 2, or 3heteroatoms selected from O, S, or N; or R₁ is aryl, arylalkyl,heteroaryl, heterocyclic, or carbocyclic; wherein R₁ may be optionallysubstituted;

R₂ is hydrogen or optionally substituted alkyl;

R₃ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

R₄ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

R₅ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

or R₃ and X, together with the atoms to which they are attached, form a3-8 membered carbocyclic, aryl, heterocyclic, or heteroaryl; each ofwhich is optionally substituted;

or X and Y, together with the atoms to which they are attached, form a3-8 membered carbocyclic, aryl, heterocyclic, or heteroaryl; each ofwhich is optionally substituted; and

R₆ is hydrogen or optionally substituted alkyl.

In certain embodiments, the invention provides a compound wherein X isCR₄ or CHR₄, and Y is NR₅.

In other embodiments, the invention provides a compound wherein R₄ ishydrogen, alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic, each ofwhich may be optionally substituted; and R₅ is hydrogen, alkyl, aryl,heteroaryl, heterocyclic, or carbocyclic, each of which may beoptionally substituted.

In certain embodiments, the invention provides a compound wherein X andY, together with the atoms to which they are attached, form a 3-8membered cycloalkyl, aryl, heterocycloalkyl, or heteroaryl; each ofwhich is optionally substituted.

In other embodiments, the invention provides a compound wherein R₃ andX, together with the atoms to which they are attached, form a 3-8membered cycloalkyl, aryl, heterocycloalkyl, or heteroaryl; each ofwhich is optionally substituted.

In some embodiments, the invention provides a compound wherein X is Nand Y is CR₅.

In a further embodiment, R₅ is alkyl, aryl, heteroaryl, heterocyclic, orcarbocyclic, each of which may be optionally substituted.

In a first embodiment, the invention provides a compound of B:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is aryl, or heteroaryl, wherein R₁ may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₃ is hydrogen or methyl;

R₄ is hydrogen or methyl; and

R₆ is hydrogen.

In one embodiment, R₁ is phenyl or pyridyl, each of which may beoptionally substituted.

In a further embodiment, R₁ is substituted with 0-4 substituents,selected from N(R_(A))(R_(A)), C(O)NH(R_(A)), alkoxy, and heterocyclic,each of which may be further substituted; wherein each R_(A) isindependently selected from alkyl, and heterocyclic.

-   -   In another further embodiment, R₁ is substituted with 0-4        substituents, selected from alkoxy,

In a second embodiment, the invention provides a compound of formula C:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is aryl, heteroaryl, which may be optionally substituted;

R₂ is hydrogen or methyl;

R₃ is hydrogen;

R₄ is hydrogen; and

R₆ is hydrogen.

In certain embodiments, R₁ is phenyl or pyridyl, each of which may beoptionally substituted.

In a further embodiment, R₁ is substituted with 0-4 substituents,selected from alkoxy, or heterocyclic, which may be further substituted.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from alkoxy,

In a third embodiment, the invention provides a compound of formula D:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic, wherein R₁may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₆ is hydrogen or optionally substituted alkyl;

each R₇ is independently alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, carbocyclic, alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl),or N(alkyl)(aryl), each of which may be optionally substituted; hal,nitro, or cyano; and

p is 0-6.

In one embodiment, R₁ is methyl, ethyl, propyl, iso-propyl, butyl,s-butyl, t-butyl, pentyl, hexyl, cyclohexyl, piperidinyl, pyrrolidino,phenyl, 1-naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl,pyridizinyl, quinolinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl,pyrrolyl, furanyl, isoquinolinyl, imiazolyl, or triazolyl, each of whichmay be optionally substituted.

In a further embodiment, R₁ is alkyl, phenyl, cyclohexyl, piperidinyl,quinolinyl, or pyridyl, each of which may be optionally substituted.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from hal, nitro, cyano, hydroxyl, amino, NH(R_(A)),N(R_(A))(R_(A)), CO₂H, C(O)R_(A), C(O)OR_(A), C(O)NH₂, C(O)NH(R_(A)),C(O)N(R_(A))(R_(A)), alkyl, aryl, arylalkyl, alkoxy, heteroaryl,heterocyclic, and carbocyclic, each of which may be further substituted;wherein each R_(A) is independently selected from alkyl, carbocyclic,aryl, heteroaryl, and heterocyclic.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from alkyl, alkoxy, hydroxyl,

In a fourth embodiment, the invention provides a compound of formula E:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic, wherein R₁may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₃ is hydrogen or optionally substituted alkyl;

R₆ is hydrogen or optionally substituted alkyl;

each R₇ is independently alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, carbocyclic, alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl),or N(alkyl)(aryl), each of which may be optionally substituted; hal,nitro, or cyano; and

p is 0-6.

In certain embodiments, R₁ is methyl, ethyl, propyl, iso-propyl, butyl,s-butyl, t-butyl, pentyl, hexyl, cyclohexyl, piperidinyl, pyrrolidino,phenyl, 1-naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl,pyridizinyl, quinolinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl,pyrrolyl, furanyl, isoquinolinyl, imiazolyl, or triazolyl, each of whichmay be optionally substituted.

In a further embodiment, R₁ is phenyl or pyridyl, each of which may beoptionally substituted.

In another further embodiment, R₁ is substituted with 0-4 substituents,selected from hal, nitro, cyano, hydroxyl, amino, NH(R_(A)),N(R_(A))(R_(A)), CO₂H, C(O)R_(A), C(O)OR_(A), C(O)NH₂, C(O)NH(R_(A)),C(O)N(R_(A))(R_(A)), alkyl, aryl, arylalkyl, alkoxy, heteroaryl,heterocyclic, and carbocyclic, each of which may be further substituted;wherein each R_(A) is independently selected from alkyl, carbocyclic,aryl, heteroaryl, and heterocyclic.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from alkoxy,

In a fifth embodiment, the invention provides a compound of formula F:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic, wherein R₁may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₅ is hydrogen, optionally substituted alkyl, optionally substitutedaralkyl, or optionally substituted carbocyclic; and

R₆ is hydrogen or optionally substituted alkyl;

each R₇ is independently alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, carbocyclic, alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl),or N(alkyl)(aryl), each of which may be optionally substituted; hal,nitro, or cyano; and

p is 0-4.

In certain embodiments, R₁ is methyl, ethyl, propyl, iso-propyl, butyl,s-butyl, t-butyl, pentyl, hexyl, cyclohexyl, piperidinyl, pyrrolidino,phenyl, 1-naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl,pyridizinyl, quinolinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl,pyrrolyl, furanyl, isoquinolinyl, imiazolyl, or triazolyl, each of whichmay be optionally substituted.

In a further embodiment, R₁ is phenyl or pyridyl, each of which may beoptionally substituted.

In another embodiment, R₁ is substituted with 0-4 substituents, selectedfrom hal, nitro, cyano, hydroxyl, amino, NH(R_(A)), N(R_(A))(R_(A)),CO₂H, C(O)R_(A), C(O)OR_(A), C(O)NH₂, C(O)NH(R_(A)),C(O)N(R_(A))(R_(A)), alkyl, aryl, arylalkyl, alkoxy, heteroaryl,heterocyclic, and carbocyclic, each of which may be further substituted;wherein each R_(A) is independently selected from alkyl, carbocyclic,aryl, heteroaryl, and heterocyclic.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from alkoxy, CO₂Me,

In a sixth embodiment, the invention provides a compound of formula F-I:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

Y is S, SO, SO₂, or O;

R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic, wherein R₁may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₆ is hydrogen or optionally substituted alkyl;

each R₇ is independently alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, carbocyclic, alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl),or N(alkyl)(aryl), each of which may be optionally substituted; hal,nitro, or cyano; and

p is 0-4.

In one embodiment, R₁ is methyl, ethyl, propyl, iso-propyl, butyl,s-butyl, t-butyl, pentyl, hexyl, cyclohexyl, piperidinyl, pyrrolidino,phenyl, 1-naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl,pyridizinyl, quinolinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl,pyrrolyl, furanyl, isoquinolinyl, imiazolyl, or triazolyl, each of whichmay be optionally substituted.

In a further embodiment, R₁ is phenyl or pyridyl, each of which may beoptionally substituted.

In another embodiment, R₁ is substituted with 0-4 substituents, selectedfrom hal, nitro, cyano, hydroxyl, amino, NH(R_(A)), N(R_(A))(R_(A)),CO₂H, C(O)R_(A), C(O)OR_(A), C(O)NH₂, C(O)NH(R_(A)),C(O)N(R_(A))(R_(A)), alkyl, aryl, arylalkyl, alkoxy, heteroaryl,heterocyclic, and carbocyclic, each of which may be further substituted;

wherein each R_(A) is independently selected from alkyl, carbocyclic,aryl, heteroaryl, and heterocyclic.

In a further embodiment, R₁ is substituted with 0-4 substituents,selected from alkoxy, CO₂Me,

In a seventh embodiment, the invention provides a compound of formula G:

or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein,

R₁ is alkyl, alkenyl, alkynyl, each containing 0, 1, 2, or 3 heteroatomsselected from O, S, or N; or R₁ is aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, wherein R₁ may be optionally substituted;

R₂ is hydrogen or optionally substituted alkyl;

R₃ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted;

R₅ is hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl,heterocyclic, or carbocyclic, each of which may be optionallysubstituted; and

R₆ is hydrogen or optionally substituted alkyl.

In one embodiment, R₁ is methyl, ethyl, propyl, iso-propyl, butyl,s-butyl, t-butyl, pentyl, hexyl, cyclohexyl, piperidinyl, pyrrolidino,phenyl, 1-naphthyl, 2-naphthyl, pyridyl, pyrimidinyl, pyrazinyl,pyridizinyl, quinolinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl,pyrrolyl, furanyl, isoquinolinyl, imiazolyl, or triazolyl, each of whichmay be optionally substituted.

In a further embodiment, R₁ is optionally substituted phenyl.

In another embodiment, R₁ is substituted with 0-4 substituents, selectedfrom hal, nitro, cyano, hydroxyl, amino, NH(R_(A)), N(R_(A))(R_(A)),CO₂H, C(O)R_(A), C(O)NH₂, C(O)NH(R_(A)), C(O)N(R_(A))(R_(A)), alkyl,aryl, arylalkyl, alkoxy, heteroaryl, heterocyclic, and carbocyclic, eachof which may be further substituted; wherein each R_(A) is independentlyselected from alkyl, carbocyclic, aryl, heteroaryl, and heterocyclic.

In certain embodiments, R₁ is substituted with 0-4 substituents,selected from alkoxy, hydroxyl,

In another embodiment, R₅ is optionally substituted phenyl or optionallysubstituted cyclopentyl.

Representative compounds of the invention include, but are not limitedto, the following compounds of Tables 1-5, which follow the examples.

The synthesis of the compounds of the invention can be found in theExamples below.

Another embodiment is a method of making a compound of any of theformulae herein using any one, or combination of, reactions delineatedherein. The method can include the use of one or more intermediates orchemical reagents delineated herein.

Another aspect is an isotopically labeled compound of any of theformulae delineated herein. Such compounds have one or more isotopeatoms which may or may not be radioactive (e.g., ³H, ²H, ¹⁴C, ¹³C ³⁵S,³²P, ¹²⁵I, and ¹³¹I) introduced into the compound. Such compounds areuseful for drug metabolism studies and diagnostics, as well astherapeutic applications.

A compound of the invention can be prepared as a pharmaceuticallyacceptable acid addition salt by reacting the free base form of thecompound with a pharmaceutically acceptable inorganic or organic acid.Alternatively, a pharmaceutically acceptable base addition salt of acompound of the invention can be prepared by reacting the free acid formof the compound with a pharmaceutically acceptable inorganic or organicbase.

Alternatively, the salt forms of the compounds of the invention can beprepared using salts of the starting materials or intermediates.

The free acid or free base forms of the compounds of the invention canbe prepared from the corresponding base addition salt or acid additionsalt from, respectively. For example a compound of the invention in anacid addition salt form can be converted to the corresponding free baseby treating with a suitable base (e.g., ammonium hydroxide solution,sodium hydroxide, and the like). A compound of the invention in a baseaddition salt form can be converted to the corresponding free acid bytreating with a suitable acid (e.g., hydrochloric acid, etc.).

Prodrug derivatives of the compounds of the invention can be prepared bymethods known to those of ordinary skill in the art (e.g., for furtherdetails see Saulnier et al., (1994), Bioorganic and Medicinal ChemistryLetters, Vol. 4, p. 1985). For example, appropriate prodrugs can beprepared by reacting a non-derivatized compound of the invention with asuitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate,para-nitrophenyl carbonate, or the like).

Protected derivatives of the compounds of the invention can be made bymeans known to those of ordinary skill in the art. A detaileddescription of techniques applicable to the creation of protectinggroups and their removal can be found in T. W. Greene, “ProtectingGroups in Organic Chemistry”, 3rd edition, John Wiley and Sons, Inc.,1999.

Compounds of the present invention can be conveniently prepared, orformed during the process of the invention, as solvates (e.g.,hydrates). Hydrates of compounds of the present invention can beconveniently prepared by recrystallization from an aqueous/organicsolvent mixture, using organic solvents such as dioxin, tetrahydrofuranor methanol.

Acids and bases useful in the methods herein are known in the art. Acidcatalysts are any acidic chemical, which can be inorganic (e.g.,hydrochloric, sulfuric, nitric acids, aluminum trichloride) or organic(e.g., camphorsulfonic acid, p-toluenesulfonic acid, acetic acid,ytterbium triflate) in nature. Acids are useful in either catalytic orstoichiometric amounts to facilitate chemical reactions. Bases are anybasic chemical, which can be inorganic (e.g., sodium bicarbonate,potassium hydroxide) or organic (e.g., triethylamine, pyridine) innature. Bases are useful in either catalytic or stoichiometric amountsto facilitate chemical reactions.

In addition, some of the compounds of this invention have one or moredouble bonds, or one or more asymmetric centers. Such compounds canoccur as racemates, racemic mixtures, single enantiomers, individualdiastereomers, diastereomeric mixtures, and cis- or trans- or E- orZ-double isomeric forms, and other stereoisomeric forms that may bedefined, in terms of absolute stereochemistry, as (R)- or (S)-, or as(D)- or (L)- for amino acids. All such isomeric forms of these compoundsare expressly included in the present invention. Optical isomers may beprepared from their respective optically active precursors by theprocedures described above, or by resolving the racemic mixtures. Theresolution can be carried out in the presence of a resolving agent, bychromatography or by repeated crystallization or by some combination ofthese techniques which are known to those skilled in the art. Furtherdetails regarding resolutions can be found in Jacques, et al.,Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). Thecompounds of this invention may also be represented in multipletautomeric forms, in such instances, the invention expressly includesall tautomeric forms of the compounds described herein (e.g., alkylationof a ring system may result in alkylation at multiple sites, theinvention expressly includes all such reaction products). When thecompounds described herein contain olefinic double bonds or othercenters of geometric asymmetry, and unless specified otherwise, it isintended that the compounds include both E and Z geometric isomers.Likewise, all tautomeric forms are also intended to be included. Theconfiguration of any carbon-carbon double bond appearing herein isselected for convenience only and is not intended to designate aparticular configuration unless the text so states; thus a carbon-carbondouble bond depicted arbitrarily herein as trans may be cis, trans, or amixture of the two in any proportion. All such isomeric forms of suchcompounds are expressly included in the present invention. All crystalforms of the compounds described herein are expressly included in thepresent invention.

The synthesized compounds can be separated from a reaction mixture andfurther purified by a method such as column chromatography, highpressure liquid chromatography, or recrystallization. As can beappreciated by the skilled artisan, further methods of synthesizing thecompounds of the formulae herein will be evident to those of ordinaryskill in the art. Additionally, the various synthetic steps may beperformed in an alternate sequence or order to give the desiredcompounds. In addition, the solvents, temperatures, reaction durations,etc. delineated herein are for purposes of illustration only and one ofordinary skill in the art will recognize that variation of the reactionconditions can produce the desired bridged macrocyclic products of thepresent invention. Synthetic chemistry transformations and protectinggroup methodologies (protection and deprotection) useful in synthesizingthe compounds described herein are known in the art and include, forexample, those such as described in R. Larock, Comprehensive OrganicTransformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts,Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons(1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents forOrganic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed.,Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons(1995), and subsequent editions thereof.

The compounds of this invention may be modified by appending variousfunctionalities via any synthetic means delineated herein to enhanceselective biological properties. Such modifications are known in the artand include those which increase biological penetration into a givenbiological system (e.g., blood, lymphatic system, central nervoussystem), increase oral availability, increase solubility to allowadministration by injection, alter metabolism and alter rate ofexcretion.

The compounds of the invention are defined herein by their chemicalstructures and/or chemical names. Where a compound is referred to byboth a chemical structure and a chemical name, and the chemicalstructure and chemical name conflict, the chemical structure isdeterminative of the compound's identity.

The recitation of a listing of chemical groups in any definition of avariable herein includes definitions of that variable as any singlegroup or combination of listed groups. The recitation of an embodimentfor a variable herein includes that embodiment as any single embodimentor in combination with any other embodiments or portions thereof.

Methods of the Invention

In another aspect, the invention provides a method of treating a diseasein a subject comprising administering to the subject a compound,pharmaceutically acceptable salt, ester or prodrug of formula A.

In one embodiment, the invention provides a method wherein the diseaseis mediated by a kinase selected from a MAP kinase, a mitotic spindlekinase, and a polo kinase.

In another embodiment, the invention provides a method wherein thedisease is mediated by a kinase selected from MPS1, ERK5, BMK1, MAPK7,polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1 mutants,DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2,PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met,Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2, Flt3, MST2,p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC. Ina further embodiment, the kinase is ERK-5, MPS1, or BMK-1.

In another embodiment, the invention provides a method wherein thedisease is cancer or a proliferation disease.

In a further embodiment, the disease is lung, colon, breast, prostate,liver, pancreas, brain, kidney, ovaries, stomach, skin, and bonecancers, gastric, breast, pancreatic cancer, glioma, and hepatocellularcarcinoma, papillary renal carcinoma, head and neck squamous cellcarcinoma, leukemias, lymphomas, myelomas, and solid tumors.

In another embodiment, the disease is inflammation, arthritis,rheumatoid arthritis, spondylarthropathies, gouty arthritis,osteoarthritis, juvenile arthritis, and other arthritic conditions,systemic lupus erthematosus (SLE), skin-related conditions, psoriasis,eczema, burns, dermatitis, neuroinflammation, allergy, pain, neuropathicpain, fever, pulmonary disorders, lung inflammation, adult respiratorydistress syndrome, pulmonary sarcoisosis, asthma, silicosis, chronicpulmonary inflammatory disease, and chronic obstructive pulmonarydisease (COPD), cardiovascular disease, arteriosclerosis, myocardialinfarction (including post-myocardial infarction indications),thrombosis, congestive heart failure, cardiac reperfusion injury, aswell as complications associated with hypertension and/or heart failuresuch as vascular organ damage, restenosis, cardiomyopathy, strokeincluding ischemic and hemorrhagic stroke, reperfusion injury, renalreperfusion injury, ischemia including stroke and brain ischemia, andischemia resulting from cardiac/coronary bypass, neurodegenerativedisorders, liver disease and nephritis, gastrointestinal conditions,inflammatory bowel disease, Crohn's disease, gastritis, irritable bowelsyndrome, ulcerative colitis, ulcerative diseases, gastric ulcers, viraland bacterial infections, sepsis, septic shock, gram negative sepsis,malaria, meningitis, HIV infection, opportunistic infections, cachexiasecondary to infection or malignancy, cachexia secondary to acquiredimmune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex),pneumonia, herpes virus, myalgias due to infection, influenza,autoimmune disease, graft vs. host reaction and allograft rejections,treatment of bone resorption diseases, osteoporosis, multiple sclerosis,cancer, leukemia, lymphoma, colorectal cancer, brain cancer, bonecancer, epithelial call-derived neoplasia (epithelial carcinoma), basalcell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer,mouth cancer, esophageal cancer, small bowel cancer, stomach cancer,colon cancer, liver cancer, bladder cancer, pancreas cancer, ovariancancer, cervical cancer, lung cancer, breast cancer, skin cancer,squamus cell and/or basal cell cancers, prostate cancer, renal cellcarcinoma, and other known cancers that affect epithelial cellsthroughout the body, chronic myelogenous leukemia (CML), acute myeloidleukemia (AML) and acute promyelocytic leukemia (APL), angiogenesisincluding neoplasia, metastasis, central nervous system disorders,central nervous system disorders having an inflammatory or apoptoticcomponent, Alzheimer's disease, Parkinson's disease, Huntington'sdisease, amyotrophic lateral sclerosis, spinal cord injury, andperipheral neuropathy, Canine B-Cell Lymphoma.

In a further embodiment, the disease is inflammation, arthritis,rheumatoid arthritis, spondylarthropathies, gouty arthritis,osteoarthritis, juvenile arthritis, and other arthritic conditions,systemic lupus erthematosus (SLE), skin-related conditions, psoriasis,eczema, dermatitis, pain, pulmonary disorders, lung inflammation, adultrespiratory distress syndrome, pulmonary sarcoisosis, asthma, chronicpulmonary inflammatory disease, and chronic obstructive pulmonarydisease (COPD), cardiovascular disease, arteriosclerosis, myocardialinfarction (including post-myocardial infarction indications),congestive heart failure, cardiac reperfusion injury, inflammatory boweldisease, Crohn's disease, gastritis, irritable bowel syndrome, leukemia,lymphoma.

In another aspect, the invention provides a method of treating a kinasemediated disorder in a subject comprising: administering to the subjectidentified as in need thereof a compound, pharmaceutically acceptablesalt, ester or prodrug of formula A.

In one embodiment, the compound is an inhibitor of MPS1, ERK5, BMK1,MAPK7, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4,PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK,cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2,Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkBor TrkC. In a further embodiment, the compound is an inhibitor of ERK-5,MPS1, or BMK-1.

In certain embodiments, the subject is administered an additionaltherapeutic agent.

In a further embodiment, the compound and the additional therapeuticagent are administered simultaneously or sequentially.

In another aspect, the invention provides a method for reducingkinase-dependent cell growth comprising contacting a cell with a kinaseinhibitor compound of formula A.

In other aspects, the invention provides a method of inhibiting kinasein a subject identified as in need of such treatment, comprisingadministering a compound of formula A.

In certain embodiments, the invention provides a method wherein thesubject is a human.

In other embodiments, the invention provides a method wherein the kinaseinhibitor has a Ki for inhibiting kinase less than about 1 micromolar.

In one embodiment, the invention provides a method of synthesizing acompound of formula A.

Another aspect of this invention provides compounds or compositions thatare inhibitors of protein kinases, and thus are useful for the treatmentof the diseases, disorders, and conditions, along with other usesdescribed herein. In certain embodiments, these compositions optionallyfurther comprise one or more additional therapeutic agents.

The present invention provides compounds and compositions that areuseful as inhibitors of protein kinases. In certain embodiments, theinvention provides compounds and compositions that are useful asinhibitors of protein kinases selected from AAK1, ABL1, ABL1(E255K),ABL1(F317I), ABL1(F317L), ABL1(H396P), ABL1(M351T), ABL1(Q252H),ABL1(T315I), ABL1(Y253F), ABL2, ACVR1, ACVR1B, ACVR2A, ACVR2B, ACVRL1,ADCK3, ADCK4, AKT1, AKT2, AKT3, ALK, AMPK-alpha1, AMPK-alpha2, ANKK1,ARK5, ASK1, ASK2, AURKA, AURKB, AURKC, AXL, BIKE, BLK, BMPR1A, BMPR1B,BMPR2, BMX, BRAF, BRAF(V600E), BRK, BRSK1, BRSK2, BTK, CAMK1, CAMK1D,CAMK1G, CAMK2A, CAMK2D, CAMK2G, CAMK4, CAMKK1, CAMKK2, CDC2L1, CDC2L2,CDK11, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, CDKL2, CDKL3, CDKL5, CHECK1,CHEK2, CIT, CLK1, CLK2, CLK3, CLK4, CSF1R, CSK, CSNK1A1L, CSNK1D,CSNK1E, CSNK1G1, CSNK1G3, CSNK2A1, CSNK2A2, CTK, DAPK1, DAPK2, DAPK3,DCAMKL1, DCAMKL2, DCAMKL3, DDR1, DDR2, DLK, DMPK, DMPK2, DRAK1, DRAK2,DYRKIA, DYRKIB, DYRK2, EGFR, EGFR (E746-A750DEL), EGFR (G719C), EGFR(G719S), EGFR(L747-E749del, A750P), EGFR(L747-S752del, P753S),EGFR(L747-T751del,Sins), EGFR(L858R), EGFR(L858R,T790M), EGFR(L861Q),EGFR(S752-I759del), EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7,EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, ERK1,ERK2, ERK3, ERK4, ERK5, ERK8, ERN1, FAK, FER, FES, FGFR1, FGFR2, FGFR3,FGFR3(G697C), FGFR4, FGR, FLT1, FLT3, FLT3(D835H), FLT3(D835Y),FLT3(ITD), FLT3(K663Q), FLT3(N841I), FLT4, FRK, FYN, GAK,GCN2(Kin.Dom.2,S808G), GRK1, GRK4, GRK7, GSK3A, GSK3B, HCK, HIPK1,HIPK2, HIPK3, HIPK4, HPK1, HUNK, ICK, IGF1R, IKK-ALPHA, IKK-BETA,IKK-EPSILON, INSR, INSRR, IRAK1, IRAK3, ITK, JAK1(JH1domain-catalytic),JAK1(JH2domain-pseudokinase), JAK2(JH1 domain-catalytic),JAK3(JH1domain-catalytic), JNK1, JNK2, JNK3, KIT, KIT(D816V),KIT(L576P), KIT(V559D), KIT(V559D,T670I), KIT(V559D,V654A), LATS1,LATS2, LCK, LIMK1, LIMK2, LKB1, LOK, LTK, LYN, LZK, MAK, MAP3K1,MAP2K15, MAP3K2, MAP3K3, MAP3K4, MAP4K2, MAP4K3, MAP4K5, MAPKAPK2,MAPKAPK5, MARK1, MARK2, MARK3, MARK4, MAST1, MEK1, MEK2, MEK3, MEK4,MEK6, MELK, MERTK, MET, MET(M1250T), MET(Y1235D), MINK, MKNK1, MKNK2,MLCK, MLK1, MLK2, MLK3, MRCKA, MRCKB, MST1, MST1R, MST2, MST3, MST4,MUSK, MYLK, MYLK2, MYO3A, MYO3B, NDR1, NDR2, NEK1, NEK2, NEK5, NEK6,NEK7, NEK9, NIM1, NLK, OSR1, p38-alpha, p38-beta, p38-delta, p38-gamma,PAK1, PAK2, PAK3, PAK4, PAK6, PAK7, PCTK1, PCTK2, PCTK3, PDGFRA, PDGFRB,PDPK1, PFTAIRE2, PFTK1, PHKG1, PHKG2, PIK3C2B, PIK3C2G, PIK3CA,PIK3CA(C420R), PIK3CA(E542K), PIK3CA(E545A), PIK3CA(E545K),PIK3CA(H1047L), PIK3CA(H1047Y), PIK3CA(M1043I), PIK3CA(Q546K), PIK3CB,PIK3CD, PIK3CG, PIK4CB, PIM1, PIM2, PIM3, PIP5K1A, PIP5K2B, PKAC-ALPHA,PKAC-BETA, PKMYT1, PKN1, PKN2, PLK1, PLK2, PLK3, PLK4, PRKCD, PRKCE,PRKCH, PRKCQ, PRKD1, PRKD3, PRKG1, PRKG2, PRKR, PRKX, PRP4, PYK2, QSK,RAF1, RET, RET(M918T), RET(V804L), RET(V804M), RIOK1, RIOK2, RIOK3,RIPK1, RIPK2, RIPK4, ROCK1, ROCK2, ROS1, RPS6KA1(Kin.Dom.1-N-terminal),RPS6KA1(Kin.Dom.2-C-terminal), RPS6KA2(Kin.Dom.1-N-terminal),RPS6KA2(Kin.Dom.2-C-terminal), RPS6KA3(Kin.Dom.1-N-terminal),RPS6KA4(Kin.Dom.1-N-terminal), RPS6KA4(Kin.Dom.2-C-terminal),RPS6KA5(Kin.Dom.1-N-terminal), RPS6KA5(Kin.Dom.2-C-terminal),RPS6KA6(Kin.Dom.1-N-terminal), RPS6KA6(Kin.Dom.2-C-terminal), SBK1,SgK085, SgK110, SIK, SIK2, SLK, SNARK, SRC, SRMS, SRPK1, SRPK2, SRPK3,STK16, STK33, STK39, SYK, TAK1, TAO1, TAOK2, TAOK3, TBK1, TEC, TESK1,TGFBR1, TGFBR2, TIE1, TIE2, TLK1, TLK2, TNIK, TNK1, TNK2, TNNI3K, TRKA,TRKB, TRKC, TSSK1B, TTK, TXK, TYK2(JH1domain-catalytic),TYK2(JH2domain-pseudokinase), TYRO3, ULK1, ULK2, ULK3, VEGFR2, WEE1,WEE2, YANK2, YANK3, YES, YSK1, YSK4, ZAK and ZAP70.

In some embodiments, the present invention provides compounds andcompositions that are useful as inhibitors of protein kinases selectedfrom MPS1, ERK5, BMK1, MAPK7, polo kinase 1, 2, 3, or 4, Ack1, Ack2,Ab1, DCAMKL1, ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1,PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3,TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx,BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H,Rsk1, SGK, TrkA, TrkB and TrkC.

As inhibitors of protein kinases, the compounds and compositions of thisinvention are particularly useful for treating or lessening the severityof a disease, condition, or disorder where a protein kinase isimplicated in the disease, condition, or disorder. In one aspect, thepresent invention provides a method for treating or lessening theseverity of a disease, condition, or disorder where a protein kinase isimplicated in the disease state. In another aspect, the presentinvention provides a method for treating or lessening the severity of akinase disease, condition, or disorder where inhibition of enzymaticactivity is implicated in the treatment of the disease. In anotheraspect, this invention provides a method for treating or lessening theseverity of a disease, condition, or disorder with compounds thatinhibit enzymatic activity by binding to the protein kinase. Anotheraspect provides a method for treating or lessening the severity of akinase disease, condition, or disorder by inhibiting enzymatic activityof the kinase with a protein kinase inhibitor.

In some embodiments, said method is used to treat or prevent a conditionselected from autoimmune diseases, inflammatory diseases, proliferativeand hyperproliferative diseases, immunologically-mediated diseases, bonediseases, metabolic diseases, neurological and neurodegenerativediseases, cardiovascular diseases, hormone related diseases, allergies,asthma, and Alzheimer's disease. In other embodiments, said condition isselected from a proliferative disorder and a neurodegenerative disorder.

One aspect of this invention provides compounds that are useful for thetreatment of diseases, disorders, and conditions characterized byexcessive or abnormal cell proliferation. Such diseases include, aproliferative or hyperproliferative disease, and a neurodegenerativedisease. Examples of proliferative and hyperproliferative diseasesinclude, without limitation, cancer. The term “cancer” includes, but isnot limited to, the following cancers: breast; ovary; cervix; prostate;testis, genitourinary tract; esophagus; larynx, glioblastoma;neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoidcarcinoma, large cell carcinoma, small cell carcinoma, lungadenocarcinoma; bone; colon; colorectal; adenoma; pancreas,adenocarcinoma; thyroid, follicular carcinoma, undifferentiatedcarcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladdercarcinoma; liver carcinoma and biliary passages; kidney carcinoma;myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccalcavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine;colon-rectum, large intestine, rectum, brain and central nervous system;chronic myeloid leukemia (CML), and leukemia. The term “cancer”includes, but is not limited to, the following cancers: myeloma,lymphoma, or a cancer selected from gastric, renal, or and the followingcancers: head and neck, oropharangeal, non-small cell lung cancer(NSCLC), endometrial, hepatocarcinoma, Non-Hodgkins lymphoma, andpulmonary.

In some embodiments, the compounds of this invention are useful fortreating cancer, such as colorectal, thyroid, breast, and lung cancer;and myeloproliferative disorders, such as polycythemia vera,thrombocythemia, myeloid metaplasia with myelofibrosis, chronicmyelogenous leukemia, chronic myelomonocytic leukemia, hypereosinophilicsyndrome, juvenile myelomonocytic leukemia, and systemic mast celldisease.

In some embodiments, the compounds of this invention are useful fortreating hematopoietic disorders, in particular, acute-myelogenousleukemia (AMLi), chronic-myelogenous leukemia (CML),acute-prornyelocytic leukemia, and acute lymphocytic leukemia (ALL).

Examples of neurodegenerative diseases include, without limitation,Alzheimer's disease.

Another aspect of this invention provides a method for the treatment orlessening the severity of a disease selected from a proliferative orhyperproliterative disease, or a neurodegenerative disease, comprisingadministering an effective amount of a compound, or a pharmaceuticallyacceptable composition comprising a compound, to a subject in needthereof.

The present invention provides compounds, compositions and methods forthe treatment of kinase related disease, particularly MPS1, ERK5, BMK1,MAPK7, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4,PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK,cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2,Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkBand TrkC kinase related diseases.

Compounds of the invention modulate the activity of kinases and, assuch, are useful for treating diseases or disorders in which kinases,contribute to the pathology and/or symptomology of the disease. Examplesof kinases that are inhibited by the compounds and compositionsdescribed herein and against which the methods described herein areuseful include, but are not limited to, MPS1, ERK5, BMK1, MAPK7, polokinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1 mutants,DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2,PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met,Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2, Flt3, MST2,p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkCkinases.

As inhibitors of protein kinases, the compounds and compositions of thisinvention are also useful in biological samples. One aspect of theinvention relates to inhibiting protein kinase activity in a biologicalsample, which method comprises contacting said biological sample with acompound of the invention or a composition comprising said compound. Theterm “biological sample”, as used herein, means an in vitro or an exvivo sample, including, without limitation, cell cultures or extractsthereof; biopsied material obtained from a mammal or extracts thereof;and blood, saliva, urine, feces, semen, tears, or other body fluids orextracts thereof. Inhibition of protein kinase activity in a biologicalsample is useful for a variety of purposes that are known to one ofskill in the art. Examples of such purposes include, but are not limitedto, blood transfusion, organ-transplantation, and biological specimenstorage.

Another aspect of this invention relates to the study of protein kinasesin biological and pathological phenomena; the study of intracellularsignal transduction pathways mediated by such protein kinases; and thecomparative evaluation of new protein kinase inhibitors. Examples ofsuch uses include, but are not limited to, biological assays such asenzyme assays and cell-based assays.

The activity of the compounds as protein kinase inhibitors may beassayed in vitro, in vivo or in a cell line. In vitro assays includeassays that determine inhibition of either the kinase activity or ATPaseactivity of the activated kinase. Alternate in vitro assays quantitatethe ability of the inhibitor to bind to the protein kinase and may bemeasured either by radiolabelling the inhibitor prior to binding,isolating the inhibitor/kinase complex and determining the amount ofradiolabel bound, or by running a competition experiment where newinhibitors are incubated with the kinase bound to known radioligands.Detailed conditions for assaying a compound utilized in this inventionas an inhibitor of various kinases are set forth in the Examples below.

In accordance with the foregoing, the present invention further providesa method for preventing or treating any of the diseases or disordersdescribed above in a subject in need of such treatment, which methodcomprises administering to said subject a therapeutically effectiveamount of a compound of the invention or a pharmaceutically acceptablesalt thereof. For any of the above uses, the required dosage will varydepending on the mode of administration, the particular condition to betreated and the effect desired.

Pharmaceutical Compositions

In another aspect, the invention provides a pharmaceutical compositioncomprising a compound of formula A, or a pharmaceutically acceptableester, salt, or prodrug thereof, together with a pharmaceuticallyacceptable carrier.

Compounds of the invention can be administered as pharmaceuticalcompositions by any conventional route, in particular enterally, e.g.,orally, e.g., in the form of tablets or capsules, or parenterally, e.g.,in the form of injectable solutions or suspensions, topically, e.g., inthe form of lotions, gels, ointments or creams, or in a nasal orsuppository form. Pharmaceutical compositions comprising a compound ofthe present invention in free form or in a pharmaceutically acceptablesalt form in association with at least one pharmaceutically acceptablecarrier or diluent can be manufactured in a conventional manner bymixing, granulating or coating methods. For example, oral compositionscan be tablets or gelatin capsules comprising the active ingredienttogether with a) diluents, e.g., lactose, dextrose, sucrose, mannitol,sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum,stearic acid, its magnesium or calcium salt and/or polyethyleneglycol;for tablets also c) binders, e.g., magnesium aluminum silicate, starchpaste, gelatin, tragacanth, methylcellulose, sodiumcarboxymethylcellulose and or polyvinylpyrrolidone; if desired d)disintegrants, e.g., starches, agar, alginic acid or its sodium salt, oreffervescent mixtures; and/or e) absorbents, colorants, flavors andsweeteners. Injectable compositions can be aqueous isotonic solutions orsuspensions, and suppositories can be prepared from fatty emulsions orsuspensions. The compositions may be sterilized and/or containadjuvants, such as preserving, stabilizing, wetting or emulsifyingagents, solution promoters, salts for regulating the osmotic pressureand/or buffers. In addition, they may also contain other therapeuticallyvaluable substances. Suitable formulations for transdermal applicationsinclude an effective amount of a compound of the present invention witha carrier. A carrier can include absorbable pharmacologically acceptablesolvents to assist passage through the skin of the host. For example,transdermal devices are in the form of a bandage comprising a backingmember, a reservoir containing the compound optionally with carriers,optionally a rate controlling barrier to deliver the compound to theskin of the host at a controlled and predetermined rate over a prolongedperiod of time, and means to secure the device to the skin. Matrixtransdermal formulations may also be used. Suitable formulations fortopical application, e.g., to the skin and eyes, are preferably aqueoussolutions, ointments, creams or gels well-known in the art. Such maycontain solubilizers, stabilizers, tonicity enhancing agents, buffersand preservatives.

Compounds of the invention can be administered in therapeuticallyeffective amounts in combination with one or more therapeutic agents(pharmaceutical combinations). For example, synergistic effects canoccur with other immunomodulatory or anti-inflammatory substances, forexample when used in combination with cyclosporin, rapamycin, orascomycin, or immunosuppressant analogues thereof, for examplecyclosporin A (CsA), cyclosporin G, FK-506, rapamycin, or comparablecompounds, corticosteroids, cyclophosphamide, azathioprine,methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid,mycophenolate mofetil, 15-deoxyspergualin, immunosuppressant antibodies,especially monoclonal antibodies for leukocyte receptors, for exampleMHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58 or their ligands, orother immunomodulatory compounds, such as CTLA41g. Where the compoundsof the invention are administered in conjunction with other therapies,dosages of the co-administered compounds will of course vary dependingon the type of co-drug employed, on the specific drug employed, on thecondition being treated and so forth.

The pharmaceutical compositions of the present invention comprise atherapeutically effective amount of a compound of the present inventionformulated together with one or more pharmaceutically acceptablecarriers. As used herein, the term “pharmaceutically acceptable carrier”means a non-toxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Thepharmaceutical compositions of this invention can be administered tohumans and other animals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments, or drops), buccally, or as an oral or nasal spray.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups andelixirs. In addition to the active compounds, the liquid dosage formsmay contain inert diluents commonly used in the art such as, forexample, water or other solvents, solubilizing agents and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, oils (in particular, cottonseed, groundnut,corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, the oralcompositions can also include adjuvants such as wetting agents,emulsifying and suspending agents, sweetening, flavoring, and perfumingagents.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectablesolution, suspension or emulsion in a nontoxic parenterally acceptablediluent or solvent, for example, as a solution in 1,3-butanediol. Amongthe acceptable vehicles and solvents that may be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

In order to prolong the effect of a drug, it is often desirable to slowthe absorption of the drug from subcutaneous or intramuscular injection.This may be accomplished by the use of a liquid suspension ofcrystalline or amorphous material with poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating excipients or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat ambient temperature but liquid at body temperature and therefore meltin the rectum or vaginal cavity and release the active compound.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using such excipients as lactoseor milk sugar as well as high molecular weight polyethylene glycols andthe like.

The active compounds can also be in micro-encapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active compound may be admixed with at least one inertdiluent such as sucrose, lactose or starch. Such dosage forms may alsocomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms may also comprisebuffering agents.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. The active componentis admixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives or buffers as may be required.Ophthalmic formulation, ear drops, eye ointments, powders and solutionsare also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to anactive compound of this invention, excipients such as animal andvegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycols, silicones, bentonites, silicic acid,talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of thisinvention, excipients such as lactose, talc, silicic acid, aluminumhydroxide, calcium silicates and polyamide powder, or mixtures of thesesubstances. Sprays can additionally contain customary propellants suchas chlorofluorohydrocarbons.

Transdermal patches have the added advantage of providing controlleddelivery of a compound to the body. Such dosage forms can be made bydissolving or dispensing the compound in the proper medium. Absorptionenhancers can also be used to increase the flux of the compound acrossthe skin. The rate can be controlled by either providing a ratecontrolling membrane or by dispersing the compound in a polymer matrixor gel.

According to the methods of treatment of the present invention,disorders are treated or prevented in a subject, such as a human orother animal, by administering to the subject a therapeuticallyeffective amount of a compound of the invention, in such amounts and forsuch time as is necessary to achieve the desired result. The term“therapeutically effective amount” of a compound of the invention, asused herein, means a sufficient amount of the compound so as to decreasethe symptoms of a disorder in a subject. As is well understood in themedical arts a therapeutically effective amount of a compound of thisinvention will be at a reasonable benefit/risk ratio applicable to anymedical treatment.

In general, compounds of the invention will be administered intherapeutically effective amounts via any of the usual and acceptablemodes known in the art, either singly or in combination with one or moretherapeutic agents. A therapeutically effective amount may vary widelydepending on the severity of the disease, the age and relative health ofthe subject, the potency of the compound used and other factors. Ingeneral, satisfactory results are indicated to be obtained systemicallyat daily dosages of from about 0.03 to 2.5 mg/kg per body weight. Anindicated daily dosage in the larger mammal, e.g. humans, is in therange from about 0.5 mg to about 100 mg, conveniently administered, e.g.in divided doses up to four times a day or in retard form. Suitable unitdosage forms for oral administration comprise from ca. 1 to 50 mg activeingredient.

In certain embodiments, a therapeutic amount or dose of the compounds ofthe present invention may range from about 0.1 mg/Kg to about 500 mg/Kg,alternatively from about 1 to about 50 mg/Kg. In general, treatmentregimens according to the present invention comprise administration to apatient in need of such treatment from about 10 mg to about 1000 mg ofthe compound(s) of this invention per day in single or multiple doses.Therapeutic amounts or doses will also vary depending on route ofadministration, as well as the possibility of co-usage with otheragents.

Upon improvement of a subject's condition, a maintenance dose of acompound, composition or combination of this invention may beadministered, if necessary. Subsequently, the dosage or frequency ofadministration, or both, may be reduced, as a function of the symptoms,to a level at which the improved condition is retained when the symptomshave been alleviated to the desired level, treatment should cease. Thesubject may, however, require intermittent treatment on a long-termbasis upon any recurrence of disease symptoms.

It will be understood, however, that the total daily usage of thecompounds and compositions of the present invention will be decided bythe attending physician within the scope of sound medical judgment. Thespecific inhibitory dose for any particular patient will depend upon avariety of factors including the disorder being treated and the severityof the disorder; the activity of the specific compound employed; thespecific composition employed; the age, body weight, general health, sexand diet of the patient; the time of administration, route ofadministration, and rate of excretion of the specific compound employed;the duration of the treatment; drugs used in combination or coincidentalwith the specific compound employed; and like factors well known in themedical arts.

The invention also provides for a pharmaceutical combinations, e.g. akit, comprising a) a first agent which is a compound of the invention asdisclosed herein, in free form or in pharmaceutically acceptable saltform, and b) at least one co-agent. The kit can comprise instructionsfor its administration.

The terms “co-administration” or “combined administration” or the likeas utilized herein are meant to encompass administration of the selectedtherapeutic agents to a single patient, and are intended to includetreatment regimens in which the agents are not necessarily administeredby the same route of administration or at the same time.

The term “pharmaceutical combination” as used herein means a productthat results from the mixing or combining of more than one activeingredient and includes both fixed and non-fixed combinations of theactive ingredients. The term “fixed combination” means that the activeingredients, e.g. a compound of the invention and a co-agent, are bothadministered to a patient simultaneously in the form of a single entityor dosage. The term “non-fixed combination” means that the activeingredients, e.g. a compound of the invention and a co-agent, are bothadministered to a patient as separate entities either simultaneously,concurrently or sequentially with no specific time limits, wherein suchadministration provides therapeutically effective levels of the twocompounds in the body of the patient. The latter also applies tococktail therapy, e.g. the administration of three or more activeingredients.

In certain embodiments, these compositions optionally further compriseone or more additional therapeutic agents. For example, chemotherapeuticagents or other antiproliferative agents may be combined with thecompounds of this invention to treat proliferative diseases and cancer.Examples of known chemotherapeutic agents include, but are not limitedto, Gleevec™, adriamycin, dexamethasone, vincristine, cyclophosphamide,fluorouracil, topotecan, taxol, interferons, and platinum derivatives.

Other examples of agents the compounds of this invention may also becombined with include, without limitation: treatments for Alzheimer'sDisease such as Aricept18 and Excelon®; treatments for Parkinson'sDisease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole,bromocriptine, pergolide, trihexephendyl, and amantadine; agents fortreating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex®and Rebif®), Copaxone®, and mitoxantrone; treatments for asthma such asalbuterol and Singulair®; agents for treating schizophrenia such aszyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agentssuch as corticosteroids, TNF blockers, IL-I RA, azathioprine,cyclophosphamide, and sulfasalazine; immunomodulatory andimmunosuppressive agents such as cyclosporin, tacrolimus, rapamycin,mycophenolate mofetil, interferons, corticosteroids, cyclophophamide,azathioprine, and sulfasalazine; neurotrophic factors such asacetylcholinesterase inhibitors, MAO inhibitors, interferons,anti-convulsants, ion channel blockers, riluzole, and antiparkinsonianagents; agents for treating cardiovascular disease such asbeta-blockers, ACE inhibitors, diuretics, nitrates, calcium channelblockers, and statins; agents for treating liver disease such ascorticosteroids, cholestyramine, interferons, and anti-viral agents;agents for treating blood disorders such as corticosteroids,antileukemic agents, and growth factors; and agents for treatingimmunodeficiency disorders such as gamma globulin. Some examples ofmaterials which can serve as pharmaceutically acceptable carriersinclude, but are not limited to, ion exchangers, alumina, aluminumstearate, lecithin, serum proteins, such as human serum albumin, buffersubstances such as phosphates, glycine, sorbic acid, or potassiumsorbate, partial glyceride mixtures of saturated vegetable fatty acids,water, salts or electrolytes, such as protamine sulfate, disodiumhydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zincsalts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, woolfat, sugars such as lactose, glucose and sucrose; starches such as cornstarch and potato starch; cellulose and its derivatives such as sodiumcarboxymethyl cellulose, ethyl cellulose and cellulose acetate; powderedtragacanth; malt; gelatin; talc; excipients such as cocoa butter andsuppository waxes, oils such as peanut oil, cottonseed oil; saffloweroil; sesame oil; olive oil; corn oil and soybean oil; glycols; such apropylene glycol or polyethylene glycol; esters such as ethyl oleate andethyl laurate, agar; buffering agents such as magnesium hydroxide andaluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline;Ringer's solution; ethyl alcohol, and phosphate buffer solutions, aswell as other non-toxic compatible lubricants such as sodium laurylsulfate and magnesium stearate, as well as coloring agents, releasingagents, coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the composition,according to the judgment of the formulator. The protein kinaseinhibitors or pharmaceutical salts thereof may be formulated intopharmaceutical compositions for administration to animals or humans.These pharmaceutical compositions, which comprise an amount of theprotein inhibitor effective to treat or prevent a proteinkinase-mediated condition and a pharmaceutically acceptable carrier, areanother embodiment of the present invention.

In another aspect, the invention provides a kit comprising a compoundcapable of inhibiting kinase activity selected from one or morecompounds of formula A, and instructions for use in treating cancer.

EXAMPLES

The compounds and processes of the present invention will be betterunderstood in connection with the following examples, which are intendedas an illustration only and not to limit the scope of the invention.Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art and such changes and modificationsincluding, without limitation, those relating to the chemicalstructures, substituents, derivatives, formulations and/or methods ofthe invention may be made without departing from the spirit of theinvention and the scope of the appended claims.

Example 1 Synthesis of Compounds of Formula I

To a stirred solution of methyl 3-(cyclopentylamino)propanoate (6.0 g,35.0 mmol) and potassium carbonate (7.3 g, 52.6 mmol) in 150 mL ofacetone was slowly added 2,4-dichloro-5-nitropyrimidine (6.8 g, 35.0mmol, dissolved in 50 mL acetone) at 0° C. The reaction mixture wasstirred and allowed to approach room temperature over a period of 12-16hours. After the reaction was complete as monitored by reverse phaseanalytical liquid-chromatography electrospray mass spectrometry (LC-MS),the solvent was removed in vacuo. The resulting slurry was then dilutedin water and brine and extracted with dichloromethane. The combinedorganic layers were dried over anhydrous sodium sulfate andconcentrated. The residue was purified by silica-gel chromatography withdichloromethane:methanol (100:1 v/v) to give the title compound I-1-a(8.0 g, 69%), MS (ESI) m/z 329 (M+H)⁺.

A mixture of compound I-1-a (7.2 g, 21.9 mmol) and iron power (2.5 g,43.8 mmol) in 200 mL of acetic acid was heated at 50° C. After thereaction was complete, as monitored by LC-MS, the solvent was removed invacuo. The residue was then purified by silica-gel chromatography withdichloromethane:methanol (20:1 v/v) to give the title compound I-1-b(2.5 g, 42%), MS (ESI) m/z 267 (M+H)⁺.

To a stirred solution of compound I-1-b (276 mg, 1.0 mmol) and MeI (71μL, 1.1 mmol) in 10 mL of dimethyl acetamide (DMA) was added NaH (50 mg,60% suspension in mineral oil) at −10° C. and the reaction was graduallywarmed to 0° C. After the reaction was complete as monitored by LC-MS,the solution was poured into ice-water and extracted with ethyl acetate.The combined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated in vacuo. The residue was purified bysilica-gel chromatography with dichloromethane:methanol (50:1 v/v) togive the title compound I-1-c (252 mg, 90%), MS (ESI) m/z 281 (M+H)⁺.

A mixture of I-1-c (26 mg, 0.09 mmol),1-(6-aminopyridin-3-yl)piperidin-4-ol (22 mg, 0.12 mmol), X-Phos (4.0mg), Pd₂(dba)₃ (5.0 mg) and K₂CO₃ (38.4 mg, 0.28 mmol) in 1.5 mL oft-BuOH was heated at 100° C. in a seal tube for 8 h. The reaction wasthen filtered through celite, eluted with dichloromethane, andconcentrated in vacuo. The residue was then purified by reverse-phaseprep-HPLC using a water (0.05% TFA)/acetonitrile (0.05% TFA) gradient toafford the title compound I-1 as the TFA salt (37 mg, 70%). ¹H NMR (600MHz, DMSO-d₆) δ 9.00 (s, br, 1H), 8.03 (s, 1H), 7.97 (d, J=9.02 Hz, 1H),7.94 (d, J=2.95 Hz, 1H), 7.38 (dd, J=9.09, 2.87 Hz, 1H), 4.77 (p,J=8.34, 8.34, 8.32, 8.32 Hz, 1H), 4.67 (d, J=4.20 Hz, 1H), 3.63-3.58 (m,3H), 3.44 (td, J=9.91, 4.15, 4.15 Hz, 2H), 3.16 (s, 3H), 2.79 (ddd,J=12.57, 10.08, 2.89 Hz, 2H), 2.58-2.55 (m, 2H), 1.97-1.89 (m, 2H),1.86-1.80 (m, 2H), 1.73-1.64 (m, 2H), 1.62-1.55 (m, 4H), 1.53-1.46 (m,2H). MS (ESI) m/z 438 (M+H)⁺.

Compounds (I-2-I-40) were synthesized using the above procedure.

I-20: ¹H NMR (400 MHz, CDCl₃) δ 1.57-2.01 (m, 6H), 2.10-2.30 (m, 2H),2.41 (t, J=12 Hz, 2H), 3.10-3.20 (m, 3H), 3.34 (s, 3H), 3.93-3.97 (m,2H), 4.63 (t, J=8 Hz, 2H), 7.73 (s, 1H), 7.77-7.80 (m, 1H), 8.14 (s,1H), 8.36 (d, J=8 Hz, 1H), 8.48 (d, J=12 Hz, 1H), 8.60 (d, J=8 Hz, 1H),9.13 (d, J=8 Hz, 1H), 12.36 (bs, 1H).

I-21: ¹H NMR (400 MHz, DMSO) δ 1.00-1.10 (m, 4H), 1.20-1.25 (m, 2H),1.30-1.56 (m, 7H), 1.90-2.00 (m, 3H), 2.90-3.00 (m, 1H), 3.16 (s, 3H),7.48-7.50 (m, 1H), 7.65-7.73 (m, 2H), 7.82 (d, J=8 Hz, 1H), 8.18 (s,1H), 8.40 (d, J=8 Hz, 1H), 8.88 (bs, 1H), 9.35 (s, 1H).

I-22: ¹H NMR (400 MHz, CDCl₃) δ 1.43-1.49 (m, 4H), 1.57-1.66 (m, 4H),1.76-1.90 (m, 4H), 2.10-2.20 (m, 2H), 2.34 (t, J=12 Hz, 2H), 2.60-2.80(m, 2H), 2.85 (s, 3H), 3.08-3.10 (m, 2H), 3.29 (s, 3H), 3.49 (s, 1H),3.50-3.60 (m, 2H), 3.85-3.87 (m, 1H), 3.90 (s, 3H), 4.11-4.16 (m, 1H),6.98 (d, J=8 Hz, 1H), 7.04 (s, 1H), 7.72-7.75 (m, 2H), 10.41 (bs, 1H).

I-23: ¹H NMR (400 MHz, CD₃OD) δ 1.53-1.67 (m, 8H), 1.75-1.79 (m, 2H),1.87-1.96 (m, 4H), 2.17-2.21 (m, 2H), 3.10-3.20 (m, 1H), 3.30 (s, 3H),3.97 (s, 3H), 4.02-4.06 (m, 1H), 7.67-7.69 (m, 2H), 7.99-8.01 (m, 1H),8.05 (s, 1H).

I-24: ¹H NMR (400 MHz, CDCl₃) δ 1.59-1.98 (m, 11H), 2.10-2.20 (m, 2H),2.36 (t, J=12 Hz, 1H), 3.09-3.15 (m, 1H), 3.29 (s, 3H), 3.89-3.92 (m,1H), 4.50-4.60 (m, 1H), 6.00 (bs, 2H), 7.65 (s, 1H), 7.69 (d, J=8 Hz,2H), 7.80 (d, J=8 Hz, 2H), 11.7 (bs, 1H).

I-26: ¹H NMR (400 MHz, CDCl₃) δ 1.51-2.13 (m, 14H), 2.95-3.01 (m, 1H),3.24 (s, 3H), 3.50-3.58 (m, 2H), 3.81-3.84 (m, 2H), 3.89-4.03 (m, 2H),5.23 (bs, 1H), 5.30 (bs, 1H), 7.87 (s, 1H).

I-27: ¹H NMR (400 MHz, CDCl₃) δ 1.15-1.25 (m, 1H), 1.43-1.67 (m, 7H),1.77-1.91 (m, 4H), 2.10-2.20 (m, 1H), 2.36 (t, J=12 Hz, 1H), 3.10-3.11(m, 1H), 3.29 (s, 3H), 3.83-3.89 (m, 1H), 3.92 (s, 3H), 4.16-4.21 (m,1H), 7.30 (d, J=8 Hz, 1H), 7.73 (s, 1H), 7.46 (s, 1H), 7.71 (d, J=8 Hz,1H), 10.37 (bs, 1H).

I-30: ¹H NMR (400 MHz, CDCl₃) δ 0.86-0.88 (m, 1H), 1.25-1.29 (m, 3H),1.54-1.70 (m, 7H), 1.81-1.99 (m, 10H), 2.17-2.22 (m, 3H), 2.36 (t, J=12Hz, 3H), 3.10 (m, 1H), 3.27 (s, 3H), 3.85-3.91 (m, 1H), 4.30-4.34 (m,1H), 5.30 (s, 1H), 7.48 (s, 1H).

I-34: ¹H NMR (400 MHz, CDCl₃) δ 1.19-1.27 (m, 4H), 1.50-1.92 (m, 8H),2.10-2.17 (m, 1H), 2.30-2.40 (m, 1H), 2.88 (s, 3H), 3.08-3.10 (m, 3H),3.26 (s, 3H), 3.32-3.44 (m, 2H), 3.59-3.75 (m, 4H), 3.81 (s, 3H),3.88-3.92 (m, 2H), 6.47 (s, 1H), 6.48 (d, J=12 Hz, 1H), 7.31 (d, 1H),7.60 (s, 1H), 10.51 (bs, 1H).

I-35: ¹H NMR (400 MHz, CDCl₃) δ 1.39-1.44 (m, 4H), 1.56-1.92 (m, 7H),2.10-2.20 (m, 1H), 2.37 (t, J=12 Hz, 1H), 3.04 (d, J=4 Hz, 3H), 3.10 (t,J=4 Hz, 1H), 3.29 (s, 3H), 3.82-3.84 (m, 1H), 3.91 (s, 3H), 4.12-4.19(m, 1H), 6.26 (bs, 1H), 7.25 (d, J=8 Hz, 1H), 7.43 (s, 1H), 7.62 (d, J=8Hz, 1H), 7.71 (s, 1H), 10.47 (bs, 1H).

I-37: ¹H NMR (400 MHz, CDCl₃) δ 1.50-1.70 (m, 6H), 1.80-2.01 (m, 6H),2.10-2.30 (m, 1H), 2.39 (t, J=12 Hz, 1H), 2.90 (s, 3H), 2.20-2.30 (m,1H), 3.39 (s, 3H), 3.90-4.00 (m, 1H), 4.30-4.50 (m, 1H), 7.40 (bs, 2H),7.78 (d, J=8 Hz, 1H), 7.82 (s, 1H), 8.10 (d, J=8 Hz, 1H), 8.70 (s, 1H).

Example 2 Synthesis of Compounds of Formula II

To a stirred solution of (S)-methyl 2-(pyrrolidin-2-yl)acetatehydrochloride (467 mg, 2.6 mmol) and DIEA (1.36 mL, 7.8 mmol) in of2-PrOH (12 mL) was added 2,4-dichloro-5-nitropyrimidine (756.5 mg, 3.9mmol) in one portion at room temperature. Then the reaction was stirredat RT. After the reaction was complete as monitored by LC-MS, theresulting mixture was diluted with ethyl acetate and washed with waterand brine, the organic layer was dried over anhydrous sodium sulfate andconcentrated in vacuo. The residue was purified by silica-gel columnchromatography with ethyl acetate and hexane ( 1/10, v/v) to give thetitle compound II-1-a (391 mg, 50%), MS (ESI) m/z 301 (M+H)⁺.

A mixture of compound II-1-a (390 mg, 1.3 mmol) and iron power (728 mg,13.0 mmol) in acetic acid (18 mL) was heated at 50° C. After thereaction was complete, the mixture was concentrated in vacuo. Then theresidue was purified by silica-gel column chromatography with methanoland dichloromethane ( 1/25, v/v) to give the title compound II-1-b (212mg, 68%), MS (ESI) m/z 239 (M+H)⁺.

To a stirred solution of compound II-1-b (95 mg, 0.4 mmol) and MeI (37μL, 0.6 mmol) in dimethyl acetamide (DMA, 4.0 mL) was added NaH (32 mgs,60% suspension in mineral oil) at −10° C. and the reaction was graduallywarmed up to 0° C. After the reaction was complete as monitored byLC-MS, the solution was poured into ice-water and extracted with ethylacetate. The organic layer was washed with brine and dried overanhydrous sodium sulfate. The solvent was removed in vacuo and the crudeproduct II-1-c was used in next step without further purification. MS(ESI) m/z 253 (M+H)⁺.

A mixture of II-1-c (30 mg, 0.12 mmol),2-methoxy-4-(4-methylpiperazin-1-yl)benzenamine (26.5 mg, 0.12 mmol),X-Phos (5.1 mg), Pd₂(dba)₃ (6.6 mg) and K₂CO₃ (49.8 mg, 0.36 mmol) int-BuOH (1.5 mL) was heated at 100° C. in a seal tube for 4 h. Then thereaction was filtered through celite and eluted with dichloromethane.The solvent was removed in vacuo and the residue was purified byreverse-phase prep-HPLC using a water (0.05% TFA)/acetonitrile (0.05%TFA) gradient to afford the title compound II-1 as TFA salt (19 mg). ¹HNMR (600 MHz, CD₃OD) δ 7.76 (s, 1H), 7.62 (s, br, 1H), 6.77 (d, J=2.4Hz, 1H), 6.67 (dd, J=2.4, 8.4 Hz, 1H), 4.08-4.06 (m, 1H), 3.95-3.85 (m,6H), 3.77 (dd, J=8.4, 12.6 Hz, 1H), 3.65-3.60 (m, 2H), 3.40-3.25 (m,5H), 3.15-3.05 (m, 2H), 2.98 (s, 3H), 2.90 (dd, J=10.8, 14.4 Hz, 1H),2.75 (d, J=15 Hz, 1H), 2.31-2.27 (m, 1H), 2.09-2.06 (m, 1H), 1.98-1.93(m, 1H), 1.75-1.72 (m, 1H). MS (ESI) m/z 438 (M+H)⁺

Compounds (II-2-II-7) were synthesized using the above procedure.

Example 3 Synthesis of Compounds of Formula III

A mixture of methyl 3-(phenylamino)propanoate (1.42 g, 7.93 mmol), DIEA(2.76 mL, 15.86 mmol) and 2,4-dichloro-5-nitropyrimidine (2.30 g, 11.90mmol) in dioxane (40 mL) was heated at 50° C. for 1 h. After thereaction was complete as monitored by TLC, the reaction solution wasconcentrated in vacuo and the residue was purified by silica-gel columnchromatography with ethyl acetate and hexane ( 1/20, v/v) to give thetitle compound III-1-a (2.5 g, 91%), MS (ESI) m/z 337 (M+H)⁺.

A mixture of compound III-1-a (2.5 g, 7.4 mmol) and iron power (4.16 g,74.0 mmol) in 100 mL of acetic acid was heated at 50° C. for 12 h. Afterthe reaction was complete as monitored by LC-MS, the mixture wasconcentrated in vacuo. Then the residue was poured into ice-water andthe solid precipitated. The precipitate was filtered, washed with waterand air dried to give the title compound II-1-b (1.75 g, 86%), MS (ESI)m/z 275 (M+H)⁺.

To a stirred suspension of compound III-1-b (549.4 mg, 2.0 mmol) and MeI(0.19 mL, 3.0 mmol) in 25.0 mL of dimethyl acetamide (DMA) was added NaH(240 mg, 60% suspension in mineral oil) at −10° C. and the reaction wasgradually warmed to 0° C. After the reaction was complete, the solutionwas poured into ice-water and extracted with ethyl acetate. The organiclayer was washed with brine and dried over anhydrous sodium sulfate.Concentrated and the crude product III-1-c was used in next step withoutfurther purification. MS (ESI) m/z 289 (M+H)⁺.

A mixture of III-1-c (29 mg, 0.1 mmol),2-methoxy-4-(4-methylpiperazin-1-yl)benzenamine (22 mg, 0.1 mmol),X-Phos (4.3 mg), Pd₂(dba)₃ (5.5 mg) and K₂CO₃ (41.5 mg, 0.3 mmol) in 1.2mL of t-BuOH was heated at 100° C. in a seal tube for 4 h. Then thereaction was filtered through celite and eluted with dichloromethane.Concentrated and the residue was purified by reverse-phase prep-HPLCusing a water (0.05% TFA)/acetonitrile (0.05% TFA) gradient to affordthe title compound III-1 as TFA salt (14 mg). ¹H NMR (600 MHz, CD₃OD) δ8.03 (s, br, 1H), 7.56-7.53 (m, 2H), 7.50-7.47 (m, 1H), 7.36 (d, J=7.2Hz, 2H), 6.94 (d, J=8.4 Hz, 1H), 6.62 (s, 1H), 6.08 (s, br, 1H), 4.17(t, J=5.4 Hz, 2H), 3.84 (s, 3H), 3.78-3.72 (m, 2H), 3.63-3.58 (m, 2H),3.35 (s, 3H), 3.28-3.22 (m, 2H), 3.06 (t, J=4.8 Hz, 2H), 3.04-2.98 (m,2H), 2.97 (s, 3H). MS (ESI) m/z 474 (M+H)⁺.

Compounds (III-2-III-5) were synthesized using the above procedure.

Example 4 Synthesis of Compounds of Formula IV

A mixture of ethyl 2-(methylamino)benzoate (1.44 g, 8.0 mmol), DIEA (2.8mL, 16.0 mmol) and 2,4-dichloro-5-nitropyrimidine (2.30 g, 12.0 mmol) in40 mL of dioxane was heated at 50° C. for 6 h. After the reaction wascomplete as monitored by TLC, the reaction solution was concentrated andthe residue was purified by silica-gel column chromatography with ethylacetate and hexane ( 1/20, v/v) to give the title compound IV-1-a (2.51g, 93%), MS (ESI) m/z 337 (M+H)⁺.

A mixture of compound IV-1-a (2.35 g, 6.98 mmol) and iron power (3.9 g,69.8 mmol) in 100 mL of acetic acid was heated at 50° C. for 9 h. Afterthe reaction was complete as monitored by LC-MS, the mixture wasconcentrated. Then the residue was poured into ice-water and the solidprecipitated. The precipitate was filtered, washed with water and driedby air to give the title compound IV-1-b (1.55 g, 85%), MS (ESI) m/z 261(M+H)⁺.

To a stirred suspension of compound IV-1-b (688 mg, 2.64 mmol) and MeI(0.25 mL, 4.0 mmol) in 40.0 mL of dimethyl acetamide (DMA) was added NaH(360 mg, 60% suspension in mineral oil) at −10° C. and the reaction wasgradually warmed up to 0° C. After the reaction was complete asmonitored by LC-MS, the solution was poured into ice-water and the solidprecipitated. The precipitate was filtered, washed with water and airdried to give the title compound IV-1-c (563 mg, 77%), MS (ESI) m/z 275(M+H)⁺.

A mixture of IV-1-c (28 mg, 0.1 mmol),2-methoxy-4-(4-methylpiperazin-1-yl)benzenamine (22 mg, 0.1 mmol),X-Phos (4.3 mg), Pd₂(dba)₃ (5.5 mg) and K₂CO₃ (41.5 mg, 0.3 mmol) in 1.2mL of t-BuOH was heated at 100° C. in a seal tube for 4 h. Then thereaction was filtered through celite and eluted with dichloromethane.The dichloromethane was removed in vacuo and the resulting crude productwas purified by reverse-phase prep-HPLC using a water (0.05%TFA)/acetonitrile (0.05% TFA) gradient to afford the title compound IV-1as TFA salt (20 mg). ¹H NMR (600 MHz, CD₃OD) δ 8.1 (s, 1H), 7.78 (dd,J=1.2, 7.8 Hz, 1H), 7.71 (d, J=7.2 Hz, 1H), 7.57-7.54 (m, 1H), 7.28-7.23(m, 2H), 6.76 (d, J=2.4 Hz, 1H), 6.67 (dd, J=1.2, 8.4 Hz, 1H), 3.92-3.86(m, 5H), 3.66-3.60 (m, 2H), 3.46 (s, 3H), 3.45 (s, 3H), 3.28-3.24 (m,2H), 3.14-3.06 (m, 2H), 2.97 (s, 3H). MS (ESI) m/z 460 (M+H)⁺.

Compounds (IV-2-IV-30) were synthesized using the above procedure.

Example 4.2 Synthesis of Compounds of Formula IV-II

Example of Synthesis of Compound IV-II-1

To a stirred solution of 2,4-dichloro-5-nitropyrimidine (2.91 g, 15.0mmol) and DIEA (3.5 mL, 20.0 mmol) in 45 mL of dioxane was added methyl2-mercaptobenzoate (1.68 g, 10.0 mmol) in 15 mL of dioxane at RT. Afterthe reaction was complete as monitored by TLC, the reaction was dilutedwith ethyl acetate and washed brine. The organic layer was dried overanhydrous Na₂SO₄ and then the solvent was removed in vacuo. The residuewas dissolved in 120 mL of acetic acid and 5.6 g of iron powder wasadded. The resulting mixture was heated at 60° C. for 7 h. After thereaction was complete as monitored by LC-MS, the mixture wasconcentrated. Then the residue was poured into ice-water and the solidprecipitated. The precipitate was filtered, washed with water and driedby air to give the title compound IV-II-1-a (2.51 g, 85%), MS (ESI)/z297 (M+H)⁺.

To a stirred solution of compound IV-II-1-a (2.22 g, 7.5 mmol) in 75 mLof dichloromethane was added trimethylaluminum solution (2.0 M intoluene, 6.0 mL) at 0° C. After 15 minutes, the ice-bath was removed andthe reaction was stirred at RT for 1 h. Then the mixture was reflux at45° C. until the reaction was complete as monitored by LC-MS. Thereaction was cooled down and quenched by 1 N HCl aqueous solution at 0°C. After removing the organic solvent, the residue was poured intoice-water and the solid precipitated. The precipitate was filtered,washed with water and dried by air to give the title compound IV-II-1-b(1.74 g, 88%), MS (ESI) m/z 264 (M+H)⁺.

To a stirred suspension of compound IV-II-1-b (394.5 mg, 1.5 mmol) andMeI (0.11 mL, 1.8 mmol) in 15.0 mL of dimethyl acetamide (DMA) was addedNaH (120 mg, 60% suspension in mineral oil) at −10° C. and the reactionwas gradually warmed up to 0° C. After the reaction was complete asmonitored by LC-MS, the solution was poured into ice-water and the solidprecipitated. The precipitate was filtered, washed with water and airdried to give the title compound IV-II-1-c (321 mg, 77%), MS (ESI) m/z278 (M+H)⁺.

A mixture of IV-II-1-c (28 mg, 0.1 mmol),2-methoxy-4-(4-methylpiperazin-1-yl)benzenamine (22 mg, 0.1 mmol),X-Phos (4.3 mg), Pd₂(dba)₃ (5.5 mg) and K₂CO₃ (41.5 mg, 0.3 mmol) in 1.2mL of t-BuOH was heated at 100° C. in a seal tube for 4 h. Then thereaction was filtered through celite and eluted with dichloromethane.The dichloromethane was removed in vacuo and the resulting crude productwas purified by preparative TLC with 3.5 N ammonia methanol solution anddichloromethane ( 1/25, v/v) to give the title compound IV-1 (8 mg). ¹HNMR (600 MHz, CDCl₃) δ 8.32 (s, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.80 (dd,J=1.8, 7.8 Hz, 1H), 7.61 (s, 1H), 7.51 (dd, J=1.8, 7.8 Hz, 1H),7.40-7.34 (m, 2H), 6.54 (dd, J=1.8, 8.4 Hz, 1H), 6.52 (d, J=1.8 Hz, 1H),3.85 (s, 3H), 3.55 (s, 3H), 3.23 (s, br, 4H), 2.69 (s, br, 4H), 2.43 (s,3H). MS (ESI) m/z 463 (M+H)⁺.

TABLE 1 Compounds of the invention Compound ID Structure SpectroscopyI-1 

MS (ESI) m/z 438 (M + H)⁺9-cyclopentyl-2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-2 

MS (ESI) m/z 494 (M + H)⁺ 4-(9-cyclopentyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide I-3 

MS (ESI) m/z 508 (M + H)⁺4-(9-cyclopentyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide I-4 

MS (ESI) m/z 522 (M + H)⁺ 4-(9-cyclopentyl-5,8-dimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4- yl)benzamide I-5 

MS (ESI) m/z 522 (M + H)⁺ 4-(9-cyclopentyl-5,7-dimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4- yl)benzamide I-6 

MS (ESI) m/z 467 (M + H)⁺ 9-cyclopentyl-2-(4-(4-hydroxypiperidin-1-yl)-2- methoxy phenyl amino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-7 

MS (ESI) m/z 441 (M + H)⁺ 9-cyclopentyl-2-(4-((2-hydroxyethyl)(methyl)amino)-2-methoxyphenyl amino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin- 6(7H)-one I-8 

MS (ESI) m/z 455 (M + H)⁺ 9-cyclopentyl-2-(4-43-hydroxypropyl)(methyl)amino)-2-methoxy phenylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5- b][1,4]diazepin-6(7H)-one I-9 

MS (ESI) m/z 481 (M + H)⁺9-cyclopentyl-2-(4-(4-hydroxy-4-methylpiperidin-1- yl)-2-methoxyphenylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-10

MS (ESI) m/z 481 (M + H)⁺9-cyclopentyl-2-(2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-11

MS (ESI) m/z 495 (M + H)⁺ 9-cyclopentyl-2-(4-(4-hydroxypiperidin-1-yl)-2- isopropoxy phenylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-12

MS (ESI) m/z 496 (M + H)⁺9-cyclopentyl-2-(4-(4-(2-hydroxyethyl)piperazin-1- yl)-2-methoxyphenylamino)-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-13

MS (ESI) m/z 495 (M + H)⁺9-cyclopentyl-2-(2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenylamino)-5-ethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-14

MS (ESI) m/z 509 (M + H)⁺9-cyclopentyl-5-ethyl-2-(4-(4-hydroxypiperidin-1- yl)-2-isopropoxyphenylamino)-8,9-dihydro-5H- pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-15

MS (ESI) m/z 452 (M + H)⁺9-cyclopentyl-5-ethyl-2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-16

MS (ESI) m/z 563 (M + H)⁺ 9-cyclopentyl-2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-5,8-dimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4] diazepin-6(7H)-one I-17

MS (ESI) m/z 549 (M + H)⁺ 9-cyclopentyl-2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-8-methyl-8,9-dihydro-5H-pyrimido[4,5- b][1,4]diazepin-6(7H)-one I-18

MS (ESI) m/z 480 (M + H)⁺9-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,8-dimethyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-19

MS (ESI) m/z 466 (M + H)⁺9-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-8-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one I-20

MS (ESI) m/z 429 (M + H)⁺.10-cyclopentyl-5-methyl-2-(quinolin-6-ylamino)- 6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-6(5H)-one I-21

MS (ESI) m/z 429 (M + H)⁺.10-cyclopentyl-5-methyl-2-(quinolin-5-ylamino)- 6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-6(5H)-one I-22

MS (ESI) m/z 534 (M + H)⁺.10-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazine- 1-carbonyl)phenylamino)-5-methyl-6a,7,8,9,9a,10- hexahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin-6(5H)-one I-23

MS (ESI) m/z 452 (M + H)⁺.4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-3-methoxybenzoic acidI-24

MS (ESI) m/z 421 (M + H)⁺.4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)benzamide I-25

MS (ESI) m/z 535 (M + H)⁺. 10-cyclopentyl-2-(4-(4-hydroxy piperidine-1-carbonyl)-2-methoxy phenylamino)-5-methyl- 6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-6(5H)-one I-26

MS (ESI) m/z 346 (M + H)⁺. 10-cyclopentyl-2-(2-hydroxyethylamino)-5-methyl- 6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin-6(5H)-one I-27

MS (ESI) m/z 451 (M + H)⁺4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-3-methoxybenzamideI-28

MS (ESI) m/z 549 (M + H)⁺.4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10-octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-N-(4-hydroxycyclohexyl)-3-methoxybenzamide I-29

MS (ESI) m/z 548 (M + H)⁺4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide I-30

MS (ESI) m/z 400 (M + H)⁺. 10-cyclopentyl-2-(4-hydroxycyclohexylamino)-5- methyl-6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-6(5H)-one I-31

MS (ESI) m/z 399 (M + H)⁺. 10-cyclopentyl-5-methyl-2-(1-methylpiperidin-4- ylamino)-6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido][5,4-b][1,4]diazepin-6(5H)-one I-32

MS (ESI) m/z 495 (M + H)⁺.4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide I-33

MS (ESI) m/z 507 (M + H)⁺. 10-cyclopentyl-2-(4-(4-hydroxypiperidin-1-yl)-2- methoxyphenyl amino)-5-methyl-6a,7,8,9,9a,10-hexahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin- 6(5H)-one I-34

MS (ESI) m/z 506 (M + H)⁺.10-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-6a,7,8,9,9a,10- hexahydrocyclopenta[e]pyrimido[5,4-b][1,4] diazepin-6(5H)-one I-35

MS (ESI) m/z 465 (M + H)⁺.4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-3-methoxy-N-methylbenzamide I-36

MS (ESI) m/z 589 (M + H)⁺. 10-cyclopentyl-2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl) piperidin-1-yl)phenylamino)- 5-methyl-6a,7,8,9,9a,10-hexa hydrocyclopenta[e] pyrimido[5,4-b][1,4]diazepin-6(5H)-oneI-37

MS (ESI) m/z 436 (M + H)⁺.6-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-N-methylnicotinamideI-38

MS (ESI) m/z 534 (M + H)⁺ 1-(4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10-octahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-3-methoxyphenyl)piperidine-4-carboxamide I-39

MS (ESI) m/z 645 (M + H)⁺ 10-cyclopentyl-2-(2-isopropoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenylamino)-5-methyl-6a,7,8,9,9a,10- hexahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-6(5H)-one I-40

MS (ESI) m/z 519 (M + H)⁺6-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4- b][1,4]diazepin-2-ylamino)-N-(1-methylpiperidin-4-yl)nicotinamide

TABLE 2 Compounds of the invention Compound ID Structure SpectroscopyII-1

MS (ESI) m/z 438 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2-d][1,4]diazepin-6(7H)-one II-2

MS (ESI) m/z 424 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2-d][1,4]diazepin-6(7H)-one II-3

MS (ESI) m/z 521 (M + H)⁺2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2-d)[1,4]diazepin-6(7H)-one II-4

MS (ESI) m/z 467 (M + H)⁺ 2-(4-(4-hydroxypiperidin-1-yl)-2-isopropoxyphenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2- d][1,4]diazepin-6(7H)-one II-5

MS (ESI) m/z 410 (M + H)⁺2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2-d][1,4]diazepin-6(7H)-one II-6

MS (ESI) m/z 453 (M + H)⁺ 2-(2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2-d][1,4]diazepin-6(7H)-one II-7

MS (ESI) m/z 522 (M + H)⁺ 2-(4-(4-(diethylamino)piperidin-1-yl)-2-isopropoxyphenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2- d][1,4]diazepin-6(7H)-one II-8

4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido(5,4-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4- yl)benzamide II-9

4-(10-cyclopentyl-5-methyl-6-oxo-5,6,6a,7,8,9,9a,10- octahydrocyclopenta[e]pyrimido[5,4-b][1,4]diazepin- 2-ylamino)-3-methoxybenzamideII-10

2-(4-(4-(dimethylamino)piperidin-1-yl)-2-isopropoxyphenylamino)-5-methyl-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo[1,2- d][1,4]diazepin-6(7H)-one

TABLE 3 Compounds of the invention Compound ID Structure SpectroscopyIII-1

MS (ESI) m/z 474 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-9-phenyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one III-2

MS (ESI) m/z 460 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-9-phenyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one III-3

MS (ESI) m/z 446 (M + H)⁺2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-5-methyl-9-phenyl-8,9-dihydro-5H-pyrimido[4,5- b][1,4]diazepin-6(7H)-oneIII-4

MS (ESI) m/z 503 (M + H)⁺ 2-(4-(4-hydroxypiperidin-1-yl)-2-isopropoxyphenylamino)-5-methyl-9-phenyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one III-5

MS (ESI) m/z 489 (M + H)⁺2-(2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenylamino)-5-methyl-9-phenyl-8,9-dihydro-5H-pyrimido[4,5- b][1,4]diazepin-6(7H)-one

TABLE 4 Compounds of the invention Compound ID Structure SpectroscopyIV-1

MS (ESI) m/z 460 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-2

MS (ESI) m/z 446 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-11-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-3

MS (ESI) m/z 489 (M + H)⁺. 2-(4-(4-hydroxypiperidin-1-yl)-2-isopropoxyphenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-4

MS (ESI) m/z 543 (M + H)⁺. 2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-5

MS (ESI) m/z 432 (M + H)⁺.2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-one IV-6

MS (ESI) m/z 475 (M + H)⁺. 2-(2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-7

MS (ESI) m/z 461 (M + H)⁺. 2-(4-(4-hydroxypiperidin-1-yl)-2-methoxyphenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-8

MS (ESI) m/z 446 (M + H)⁺.5-ethyl-2-(5-(4-hydroxypiperidin-1-yl)pyridin-2-ylamino)-11-methyl-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-oneIV-9

MS (ESI) m/z 475 (M + H)⁺. 5-ethyl-2-(4-(4-hydroxypiperidin-1-yl)-2-methoxyphenylamino)-11-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-10

MS (ESI) m/z 460 (M + H)⁺. 2-(2-ethoxy-4-(4-methylpiperazin-1-yl)phenylamino)-11-methyl-5H-benzole[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-11

MS (ESI) m/z 474 (M + H)⁺. 2-(2-isopropoxy-4-(4-methylpiperazin-1-yl)phenylamino)-11-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11lH)-one IV-12

MS (ESI) m/z 474 (M + H)⁺. 11-ethyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-13

MS (ESI) m/z 460 (M + H)⁺. 11-ethyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-oneIV-14

MS (ESI) m/z 474 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-4,5,11-trimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-15

MS (ESI) m/z 460 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-4,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-16

MS (ESI) m/z 474 (M + H)⁺.11-isopropyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5H-benzo[e]pyrimido(5,4- b][1,4]diazepin-6(11H)-oneIV-17

MS (ESI) m/z 488 (M + H)⁺.11-isopropyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-18

MS (ESI) m/z 514 (M + H)⁺.11-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-19

MS (ESI) m/z 500 (M + H)⁺.11-cyclopentyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-oneIV-20

MS (ESI) m/z 478 (M + H)⁺. 9-fluoro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-21

MS (ESI) m/z 464 (M + H)⁺. 9-fluoro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-11-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-22

MS (ESI) m/z 495 (M + H)⁺. 8-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-23

MS (ESI) m/z 481 (M + H)⁺. 8-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-11-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-24

MS (ESI) m/z 460 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-8,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-25

MS (ESI) m/z 474 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,8,11-trimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-26

MS (ESI) m/z 461 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dimethyl-5H-pyrido[3,4-e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-27

MS (ESI) m/z 447 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazin-1-yl]phenylamino)-11-methyl-5H-pyrido[3,4-e]pyrimido[5,4-b][1,4)diazepin-6(11H)-one IV-28

MS (ESI) m/z 420 (M + H)⁺. methyl4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)- 3-methoxybenzoate IV-29

MS (ESI) m/z 488 (M + H)⁺. 2-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-30

MS (ESI) m/z 476 (M + H)⁺. 4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-N-(2-(dimethylamino)ethyl)-3-methoxybenzamide IV-31

MS (ESI) m/z 494 (M + H)⁺9-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-32

MS (ESI) m/z 536 (M + H)⁺ 11-benzyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-33

MS (ESI) m/z 522 (M + H)⁺ 11-benzyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-oneIV-34

MS (ESI) m/z 406 (M + H)⁺ 4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)- 3-methoxybenzoic acidIV-35

MS (ESI) m/z 420 (M + H)⁺ methyl 4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)- 3-methoxybenzoate IV-36

MS (ESI) m/z 406 (M + H)⁺ 3-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)- 4-methoxybenzoic acidIV-37

MS (ESI) m/z 542 (M + H)⁺2-(2-methoxy-4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-38

MS (ESI) m/z 571 (M + H)⁺ 2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin- 6(11H)-one IV-39

MS (ESI) m/z 502 (M + H)⁺2-(4-(3-(dimethylamino)pyrrolidine-1-carbonyl)-2-methoxyphenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-40

MS (ESI) m/z 502 (M + H)⁺ 4-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide IV-41

MS (ESI) m/z 502 (M + H)⁺ 3-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-4-methoxy-N-(1-methylpiperidin-4-yl)benzamide IV-42

MS (ESI) m/z 571 (M + H)⁺ 2-(2-methoxy-5-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin- 6(11H)-one IV-43

MS (ESI) m/z 502 (M + H)⁺2-(5-(3-(dimethylamino)pyrrolidine-1-carbonyl)-2-methoxyphenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-44

MS (ESI) m/z 476 (M + H)⁺ 3-(5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-2-ylamino)-N-(2-(dimethylamino)ethyl)-4-methoxybenzamide IV-45

MS (ESI) m/z 518 (M + H)⁺2-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methoxyphenylamino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-46

MS (ESI) m/z 446 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one IV-47

MS (ESI) m/z 432 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5H-benzo[e]pyrimido[5,4- b][1,4]diazepin-6(11H)-oneIV-II-1

¹H NMR (600 MHz, CDCl₃) δ 8.32 (s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.80(dd, J = 1.8, 7.8 Hz, 1H), 7.61 (s, 1H), 7.51 (dd, J = 1.8, 7.8 Hz, 1H),7.40-7.34 (m, 2H), 6.54 (dd, J = 1.8, 8.4 Hz, 1H), 6.52 (d, J = 1.8 Hz,1H), 3.85 (s, 3H), 3.55 (s, 3H), 3.23 (s, br, 4H), 2.69 (s, br, 4H),2.43 (s, 3H). MS (ESI) m/z 463 (M + H)⁺2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methylbenzo[f]pyrimido[4,5- b][1,4]thiazepin-6(5H)-oneIV-II-2

MS (ESI) m/z 449 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)benzo[f]pyrimido[4,5- b][1,4]thiazepin-6(5H)-one IV-II-3

MS (ESI) m/z 433 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)benzo[f]pyrimido[4,5- b][1,4]oxazepin-6(5H)-one IV-II-4

MS (ESI) m/z 477 (M + H)⁺ 2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methylbenzo[f]pyrimido[4,5- b][1,4]oxazepin-6(5H)-oneVII-1

2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-9-phenyl-5H-pyrimido[5,4-e][1,4]diazepin-6(7H)-one VII-2

3-methoxy-4-(5-methyl-6-oxo-9-phenyl-6,7-dihydro-5H-pyrimido[5,4-e][1,4)diazepin-2-ylamino)-N-(1-methylpiperidin-4-yl)benzamide VII-3

4-(9-cyclopentyl-7-ethyl-5-methyl-6-oxo-6,7-dihydro-5H-pyrimido[5,4-e][1,4]diazepin-2-ylamino)-3-hydroxy-N-(1-methylpiperidin-4- yl)benzamide VII-4

4-(7-ethyl-5-methyl-6-oxo-9-phenyl-6,7-dihydro-5H-pyrimido[5,4-e][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide VII-5

4-(9-cyclopentyl-5-methyl-6-oxo-6,7-dihydro-5H-pyrimido[5,4-e][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide

TABLE 5 Compounds of the Invention Compound ID Structure SpectroscopyV-1

MS (ESI) m/z 430 (M + H)⁺ V-2

MS (ESI) m/z 494 (M + H)⁺ V-3

MS (ESI) m/z 526 (M + H)⁺ V-4

MS (ESI) m/z 498 (M + H)⁺ V-5

MS (ESI) m/z 431 (M + H)⁺ V-6

MS (ESI) m/z 495 (M + H)⁺ V-7

MS (ESI) m/z 425 (M + H)⁺ V-8

MS (ESI) m/z 425 (M + H)⁺ V-9

MS (ESI) m/z 432 (M + H)⁺ V-10

MS (ESI) m/z 430 (M + H)⁺ V-11

MS (ESI) m/z 460 (M + H)⁺ V-12

MS (ESI) m/z 367 (M + H)⁺ V-13

MS (ESI) m/z 402 (M + H)⁺ V-14

MS (ESI) m/z 445 (M + H)⁺ V-15

MS (ESI) m/z 444 (M + H)⁺ V-16

MS (ESI) m/z 411 (M + H)⁺ V-17

MS (ESI) m/z 411 (M + H)⁺ V-18

MS (ESI) m/z 530 (M + H)⁺ V-19

MS (ESI) m/z 526 (M + H)⁺ V-20

MS (ESI) m/z 256 (M + H)⁺ V-21

MS (ESI) m/z 546 (M + H)⁺ V-22

MS (ESI) m/z 447 (M + H)⁺ V-23

MS (ESI) m/z 446 (M + H)⁺ V-24

MS (ESI) m/z 459 (M + H)⁺ V-25

MS (ESI) m/z 492 (M + H)⁺ V-26

MS (ESI) m/z 458 (M + H)⁺ V-27

¹H NMR (600 MHz, CDCl₃) δ 8.08 (s, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.20(d, J = 5.4 Hz, 1H), 7.00 (d, J = 5.4 Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H),6.66 (dd, J = 9.0, 2.4 Hz, 1H), 3.90 (s, 3H), 3.88-3.85 (m, 2H), 3.64-3.60 (m, 2H), 3.51 (s, 3H), 3.36 (s, 3H), 3.28-3.26 (m, 2H), 3.12- 3.06(m, 2H), 2.98 (s, 3H). MS (ESI) m/z 466 (M + H)⁺ V-28

MS (ESI) m/z 481 (M + H)⁺

Example 7 Mps1 (TTK) Cellular Assay—Mitotic Escape Assay

Hela (or U2OS cells) were plated at roughly 30-35% cell density. After24 hours the medium* was removed and fresh medium supplemented with 2.5mM thymidine was added to arrest cells at the G1/S transition. After 24hours in thymidine block the medium was removed, the cells were washed3× with PBS and replaced with medium supplemented with 330 nM nocodazole(Noc). The cells were incubated with nocodazole for 16-18 hours toproduce a mitotic arrest. The medium was then removed carefully andreplaced with medium supplemented with 330 nM nocodazole and testcompound at the desired concentration (with the final concentration ofDMSO below 0.2%). After 2 hours, the cells were harvested, lysed in RIPAbuffer, and the levels of cyclin B or phosphorylated Histone 3 (Ser10)determined by western blotting. Alternatively, cells were treated oncoverslips, fixed, and phosphorylated Histone 3 levels determined byimmunofluorescence. See FIG. 1. *Hela/U2OS medium—Dulbecco's ModifiedEagle's Medium (DMEM, Sigma), 10% fetal bovine serum, 1%penicillin/streptomycin

Example 8 Plk1 Cellular Assay—Mitotic Arrest Assay

Hela cells were plated at roughly 80% cell density on poly-lysine coatedglass coverslips. After 24 hours the medium* was removed and freshmedium supplemented with test compounds was added. Twenty-four hourspost-treatment the medium was removed, the coverslips were washed oncewith phosphate-buffered saline (PBS), pH 7.4 and the cells fixed for 10minutes at room temperature using the following fixative solution: 100mM K-Pipes, pH 6.8, 10 mM EGTA, 1 mM MgCl₂, 0.2% Triton X-100, 3%formaldehyde. The coverslips were washed 3× with Tris-buffered salinesolution (50 mM Tris-HCl pH 7.4, 150 mM NaCl) containing 0.1% TritonX-100 (TBST). The samples were blocked using 2% bovine serum albumin(BSA) in TBST. The samples were then incubated with aphosphorylation-specific antibody against histone 3 (phospho H3)serine-10 (Upstate, 1:500-1:1000) in blocking solution. Cells can alsooptionally be stained for tubulin as well using appropriate antibodies.After a 2-hr. incubation at room temperature (or 4° C. overnight), thesamples were washed 3× with TBST. The samples were then incubated withan appropriate secondary antibody in blocking solution for 1-2 hrs atroom temperature (or 4° C. overnight). The samples were washed 3× withTBST and then incubated with Hoechst 33342 stain (Invitrogen,1:1000-1:2000) in TBST for 15 minutes at room temperature. The sampleswere washed 3× with TBST and mounted onto glass slides using ProlongGold Antifade Reagent (Invitrogen). See FIGS. 2 and 3. *Hela/U2OSmedium—Dulbecco's Modified Eagle's Medium (DMEM, Sigma), 10% fetalbovine serum, 1% penicillin/streptomycin

Example 9 In Vitro Mps1 Kinase Assay—Invitrogen Mps1 (TTK) LanthaScreenActivity Assay

Kinase reactions were carried out at room temperature with the followingcomponents: 1× kinase reaction buffer, 5 μg/mL (40 nM) Mps1 kinase, 200nM AF-647 E4Y substrate, and 1 μM ATP (K_(m,app)<1 μM). After one hour apreparation of EDTA (20 mM) and Eu-PY20 Tb-labeled antibody (4 nM) inTR-FRET dilution buffer was added. The final concentration of EDTA andEu-PY20 in the reaction mixture is 10 mM and 2 nM respectively. Thereaction mixture was incubated at room temperature for 30 minutes beforebeing read on a plate reader configured for LanthaScreen™ TR-FRET.Kinase reactions were run over several concentrations of inhibitor toobtain dose-dependent curves as seen in FIGS. 4, 5 and 6.

INCORPORATION BY REFERENCE

The contents of all references (including literature references, issuedpatents, published patent applications, and co-pending patentapplications) cited throughout this application are hereby expresslyincorporated herein in their entireties by reference. Unless otherwisedefined, all technical and scientific terms used herein are accorded themeaning commonly known to one with ordinary skill in the art.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents of the specificembodiments of the invention described herein. Such equivalents areintended with be encompassed by the following claims.

1. A compound of formula A:

or a pharmaceutically acceptable salt, ester or prodrug thereof,wherein, A is a single bond; B is a single bond; R′ is H or alkyl; L isabsent; R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic;wherein R₁ may be optionally substituted; R₂ is hydrogen or optionallysubstituted alkyl; R₃ is hydrogen, alkyl, alkenyl, aryl, arylalkyl,heteroaryl, heterocyclic, or carbocyclic, each of which may beoptionally substituted; or X and Y, together with the atoms to whichthey are attached, form a 3-8 membered carbocyclic, aryl, heterocyclic,or heteroaryl; each of which is optionally substituted; and R₆ ishydrogen or optionally substituted alkyl. 2-20. (canceled)
 21. Thecompound of claim 1, of formula E:

or a pharmaceutically acceptable salt, ester or prodrug thereof,wherein, R₁ is alkyl, aryl, heteroaryl, heterocyclic, or carbocyclic,wherein R₁ may be optionally substituted; R₂ is hydrogen or optionallysubstituted alkyl; R₃ is hydrogen or optionally substituted alkyl; R₆ ishydrogen or optionally substituted alkyl; each R₇ is independentlyalkyl, alkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, carbocyclic,alkoxy, NH(alkyl), NH(aryl), N(alkyl)(alkyl), or N(alkyl)(aryl), each ofwhich may be optionally substituted; hal, nitro, or cyano; and p is 0-6.22. The compound of claim 21, wherein R₁ is methyl, ethyl, propyl,iso-propyl, butyl, s-butyl, t-butyl, pentyl, hexyl, cyclohexyl,piperidinyl, pyrrolidino, phenyl, 1-naphthyl, 2-naphthyl, pyridyl,pyrimidinyl, pyrazinyl, pyridizinyl, quinolinyl, thienyl, thiazolyl,oxazolyl, isoxazolyl, pyrrolyl, furanyl, isoquinolinyl, imiazolyl, ortriazolyl, each of which may be optionally substituted.
 23. The compoundof claim 22, wherein R₁ is phenyl or pyridyl, each of which may beoptionally substituted.
 24. The compound of claim 23, wherein R₁ issubstituted with 0-4 substituents, selected from hal, nitro, cyano,hydroxyl, amino, NH(R_(A)), N(R_(A))(R_(A)), CO₂H, C(O)R_(A),C(O)OR_(A), C(O)NH₂, C(O)NH(R_(A)), C(O)N(R_(A))(R_(A)), alkyl, aryl,arylalkyl, alkoxy, heteroaryl, heterocyclic, and carbocyclic, each ofwhich may be further substituted; wherein each R_(A) is independentlyselected from alkyl, carbocyclic, aryl, heteroaryl, and heterocyclic.25. The compound of claim 24, wherein R₁ is substituted with 0-4substituents, selected from alkoxy,

26-43. (canceled)
 44. A pharmaceutical composition comprising a compoundof claim 1, or a pharmaceutically acceptable ester, salt, orprodrug-thereof, together with a pharmaceutically acceptable carrier45-61. (canceled)
 62. A kit comprising a compound capable of inhibitingkinase activity selected from one or more compounds of claim 1, andinstructions for use in treating cancer.
 63. A method of synthesizing acompound of formula A.